



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

1/46

ACGTTGACAC AGGAATGAAG AGTGATTGG CTGAATCTTC AAGCAGAGGC GATATTGACC 60  
ATGTGCTTTT TAAATTGGCC TGCCTGACCC GCCCACTTGG TGTAAGAAGAA GAACCGGCCA 120  
AAGGAGGGC CTGAAGGACC TCCACAGGAG TGTGAGCAGC ACTGCTTCAG CAACAAAGCC 180  
TCAGGTCCAC ATCTTGGGAA GAAT ATG GCC ACT TCC TGG GGG GCT GTC TTC 231  
Met Ala Thr Ser Trp Gly Ala Val Phe  
1 5  
ATG CTG ATC ATA GCC TGC GTT GGC AGC ACT GTC TTC TAC AGA GAA CAG 279  
Met Leu Ile Ile Ala Cys Val Gly Ser Thr Val Phe Tyr Arg Glu Gln  
10 15 20 25  
CAG ACC TGG TTT GAA GGT GTC TTC TTG TCT TCC ATG TGC CCC ATT AAT 327  
Gln Thr Trp Phe Glu Gly Val Phe Leu Ser Ser Met Cys Pro Ile Asn  
30 35 40  
GTC AGT GCC GGC ACC TTT TAT GGA ATT ATG TTT GAT GCG GGC AGC ACT 375  
Val Ser Ala Gly Thr Phe Tyr Gly Ile Met Phe Asp Ala Gly Ser Thr  
45 50 55  
GGA GCT CGG ATT CAT GTT TAC ACT TTT GTG CAG AAA ACA GCA GGA CAG 423  
Gly Ala Arg Ile His Val Tyr Thr Phe Val Gln Lys Thr Ala Gly Gln  
60 65 70

FIG. 1A



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

2/46

ctc ccc ttt ctg gaa ggt gaa att ttt gat tct gtg aag ccg gga ctt	471
Leu Pro Phe Leu Glu Gly Glu Ile Phe Asp Ser Val Lys Pro Gly Leu	
75 80 85	
TCT GCT TTT GTG GAT CAG CCC AAA CAG GGT GCT GAG ACT GTC CAG GAG	519
Ser Ala Phe Val Asp Gln Pro Lys Gln Gly Ala Glu Thr Val Gln Glu	
90 95 100 105	
CTC TTG GAG GTG GCC AAA GAC TCG ATC CCC AGA AGC CAC TGG GAA AGG	567
Leu Leu Glu Val Ala Lys Asp Ser Ile Pro Arg Ser His Trp Glu Arg	
110 115 120	
ACC CCG GTG GTT CTG AAA GCA ACG GCC GGA CTC CGT TTG CTG CCT GAG	615
Thr Pro Val Val Leu Lys Ala Thr Ala Gly Leu Arg Leu Leu Pro Glu	
125 130 135	
CAG AAA GCC CAG GCT CTG CTC TTG GAG GTA GAG GAG ATC TTC AAG AAT	663
Gln Lys Ala Gln Ala Leu Leu Leu Glu Val Glu Glu Ile Phe Lys Asn	
140 145 150	
TCA CCT TTC CTG GTC CCA GAT GGC AGC AGC GTT AGC ATC ATG GAT GGG TCC	711
Ser Pro Phe Leu Val Pro Asp Gly Ser Val Ser Ile Met Asp Gly Ser	
155 160 165	

FIG. 1B



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

3/46

TAT GAA GGC ATA CTA GCC TGG GTT ACC GTG AAC TTT CTA ACA GGT CAG	759
Tyr Glu Gly Ile Leu Ala Trp Val Thr Val Asn Phe Leu Thr Gly Gln	
170 175 180 185	
CTG CAT GGT CGT GGC CAG GAG ACT GTG GGG ACC CTT GAC CTG GGG GGT	807
Leu His Gly Arg Gly Gln Gly Thr Val Gly Thr Leu Asp Leu Gly Gly	
190 195 200	
GCC TCC ACC CAA ATC ACG TTT CTA CCC CAG TTT GAG AAA ACC CTG GAA	855
Ala Ser Thr Gln Ile Thr Phe Leu Pro Gln Phe Glu Lys Thr Leu Glu	
205 210 215	
CAA ACA CCT AGG GGC TAC CTC ACT ACT TCC TTT GAG ATG TTT AAC AGC ACT	903
Gln Thr Pro Arg Gly Tyr Leu Thr Ser Phe Glu Met Phe Asn Ser Thr	
220 225 230	
TTT AAG CTC TAT ACA CAT AGT TAC TTT GGA CTG AAA GCT GCA	951
Phe Lys Leu Tyr Thr His Ser Tyr Leu Gly Phe Gly Leu Lys Ala Ala	
235 240 245	
AGA CTG GCA ACT CTG GGA GCC CTG GAA GCA AAA GGG ACT GAT GGA CAT	999
Arg Leu Ala Thr Leu Gly Ala Leu Glu Ala Lys Gly Thr Asp Gly His	
250 255 260 265	

FIG. 1C



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS


Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

4/46

ACG TTT CGA AGT GCC TGT TTA CCA AGA TGG TTG GAA GCA GAG TGG ATC	1047
Thr Phe Arg Ser Ala Cys Leu Pro Arg Trp Leu Glu Ala Glu Trp Ile	270 275 280
TTT GGG GGT GTG AAA TAC CAG CAG TAT GGT GGT AAC CAA GAA GGG GAG ATG	1095
Phe Gly Gly Val Lys 285 Tyr Tyr Gln Tyr Gly Gly Asn Gln Glu Gly Glu Met	290 295
GGC TTT GAA CCC TGC TAT TAT GCG GAA GTG CTG AGG GTA GAA GGG AAA	1143
Gly Phe Glu Pro Cys Tyr Ala Glu Val Leu Arg Val Val Gln Gly Lys	300 305 310
CTT CAC CAG CCA GAA GAA GTC CGA GGA AGC GCC TTC TAC GCT TTC TCT	1191
Leu His Gln Pro Glu Glu Val Arg Gly Ser Ala Phe Tyr Ala Phe Ser	315 320 325
TAC TAC TAC GAT CGA GCC GCT GAC ACA CAC CAC TTG ATC GAT TAT GAA AAG	1239
Tyr Tyr Tyr Asp Arg Ala Ala Asp Thr His Leu Ile Asp Tyr Glu Lys	330 335 340 345
GGC GGG GTT TTA AAA GTT GAA GAT TTT GAA AGA AAA GCC AGA GAA GTG	1287
Gly Gly Val Leu Lys Val Glu Asp Phe Glu Arg Lys Ala Arg Glu Val	350 355 360

FIG. 1D



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

5/46

TGT GAC AAC TTG GGG AGC TTC TCC TCG GGC AGT CCT TTC CTC TGC ATG	1335
Cys Asp Asn Leu Gly Ser Phe Ser Ser Gly Ser Pro Phe Leu Cys Met	365 370 375
GAC CTC ACT TAC ATC ACA GCC CTG TTG AAA GAT GGT TTG GGC TTT GCC	1383
Asp Leu Thr Tyr Ile Thr Ala Leu Leu Lys Asp Gly Leu Gly Phe Ala	380 385 390
GAA CGG CAC CCT CTT ACA GCT CAC AAA GAA AGT GAA CAA CAT AGA GAC	1431
Glu Arg His Pro Leu Thr Ala His Lys Lys Glu Ser Glu Gln His Arg Asp	395 400 405
TGG TTG GGC CTT GGG GGC CAC CTT TCA CCT GCT CCA GTC TCT GGG CAT	1479
Trp Leu Gly Leu Gly Gly His Leu Ser Pro Ala Pro Val Ser Gly His	410 415 420 425
CAC CAG CTG AGG CCA AGC TCC ACC TCT GAA GCC TGC ATT TCT GAA CCA	1527
His Gln Leu Arg Pro Ser Ser Thr Ser Ser Glu Ala Cys Ile Ser Glu Pro	430 435 440
GTT TTC TCA CAG GAA GGC GTG GAC TCA GAG ACA TTT TCT GAC CTC TCT	1575
Val Phe Ser Gln Glu Gly Val Asp Ser Glu Thr Phe Ser Asp Leu Ser	445 450 455

FIG. 1E



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

6/46

GGA AAA GCC TGG CCC GAA ACC CGT TAACTGGTTT TATAAGGAGG GAGGGGTTTT 1629  
Gly Lys Ala Trp Pro Glu Thr Arg 465  
460  
TAGATGAGTC TTGCTCTTGA GCTAGTGAT TTGGGCTTCA ATGATTGCA CATCTAATGT 1689  
GAATAGCTCC TAACCACTTG GTGGGTGCAT GGCTGGCACC AGACTGTAAA TCTTTTGGGA 1749  
TTCTTTGTAC AGAGTCCTGC AAAGGAAAAA AGAGAAAAGG TTGGGAACTC CATGCTAGAT 1809  
TGCGAGTTCA GAGACAGGTC CCTGGGGACC AAAGAACAAT CTCGTTTCAA CCCTTGGATG 1869  
CCTCATTGCT TTGAATGGAT TCATTTTTCG TTATAAGCTG ATTTACTGAA ATCCCATAAC 1929  
CCATCAATGC TGTAAATTTT TTTCTTCCTA CCTTATTAC ATCCCTACC CTAAAAGCCT 1989  
GGGGGAAATA CCTGGTTTTC CTCCCCTCT ATAATTGAGA AAGAGGGGGG AAAAGATACT 2049  
GTATTAGAAT TTGTGTGATC CTGTGGCACA ATAGATCAAC CAACCCATT AAAGCTTAAA 2109  
AAAAA  
2119

FIG. 1F



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

7/46

peaNTase	1	---MELLIKLITFLLFSMPAITSSQYLGNNLLTSRKIFLKQEEISSYAVVFDAGSTGSR
potapyrase	1	MLNQNSHFIFII LAIFLVLP LSLSKNVNAQIPLRRHLLSHESE--HYAVIFDAGSTGSR
mNTase	1	MATSWGAVFMLIIACVGSTVFYREQQTWFEGVFLSSMCPINVSAGTFYGIMFDAGSTGTR
yGDPase	1	KTPEDISILPVNDEPGYLQDSKTEQNYPELADAVKSQTSQTCSEEHKYVIMIDAGSTGSR
peaNTase	57	IHVYHFNQNLDDLHIGKGV EY YNKITPGLSSYANNPEQA AKSLIPLLEQAEDVVPDDLQP
potapyrase	59	VHVFDFDEKLG L LPIGN NIEYFMATEPGLSSYAEDPKAAANSL EPLLDGAEGVVPQELQS
mNTase	61	IHVYTFVQKTAGQLPFL EGEI FDSVKPGLSAFVDQPKQGAETVQELL E VAKDSIPRSHWE
yGDPase	61	VHIYKFDVCTS--PPTLLDEK FDMLEPGLSSFD TDSVGAANSLDPL LKVAMNYVPIKARS
peaNTase	117	KTPVRLGATAGLRLLNGDASEKILQSVRDMLSNRSTF-NVQPD AVSII DGTQEGSYLWVT
potapyrase	119	ETPLELGATAGLRMLKGDAAEKILQAVRNLVKNQSTF-HSKDQWVTIL DGTQEGSYMWA A
mNTase	121	RTPVVLKATAGLRLLPEQKAQALLLEVEE I FKN-SPF-LVPDGSVSIMDGSYEGILAWVT
yGDPase	119	CTPVAVKATAGLRLLGDAKSSKILSAVRDHL EKDYPFPVVEGDGVSIMGGDEEGVFAWIT

FIG. 2A



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

8/46

peaNTase 176 VNYALGNLGKKYTK--TVGVIDLGGSVQMAYAVSKKTAKNAPKVADGDDPYIKRVVLKG  
potapyrase 178 INYLGNLGKDYKS--TTATIDLGGSVQMAYAISNEQFAKAPQNEDG-EPYVQQKHLMS  
mNTase 179 VNFLTGQLHGRQGE--TVGTLDLGGASTQITFLPQFEK-----TLEQTPRGYLTSFEMFN  
YGDase 179 TNYLLGNIGANGPKLPTAAVFDLGGSTQIVFEP-----TFPINEKMVDGEHKF--DLKFGD  
  
peaNTase 234 IPYDLYVHSYLHFGREASRAEILKL-----TPRSPNPCLLAFNGIY  
potapyrase 235 KDYNLYVHSYLYNYGQLAGRAEIFKA-----SRNESNPCALEGCDGY  
mNTase 232 STFKLYTHSYLGFGLKAARLATLGA-----LEAKGT---DGHTFRS  
YGDase 234 ENYTLYQFSHLGYGLKEGRNKVNSVLENALKDGKILKGDNTKTHQLSSPCLPPKVNATN  
  
peaNTase 276 TYSGEEFKATAYTSGA-----NFNKCKNTIRKALKLNYPCPYQNCTFGGIWNGGGN---  
potapyrase 277 SYGGVDYKVKAPKKS-----SWKRCRRLTRHALKINAKCNIEECTFNGVWNGGGD---  
mNTase 270 ACLPRWLEAEWIFGGV-----KYQYGGNQEGEMGFEPCYAEVLRVVQGKLHQPPEVR---  
YGDase 294 EKVTLESKETYTIDFIGPDEPSGAQCRFLTDEILNKDAQCSPPCSFNGVHQPSLVRTFK

FIG. 2B



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

9/46



peaNTase	328	<u>GQKNLFASSFFYL</u> <u>PEDTGMVDA</u> <u>STPNFILRPVDIETKAKEACALNFEDAKSTYFFLDKK</u>
potapyrase	329	<u>GQKNIHASSFFYDIGAQVGIVDTKFP</u> <u>SALAKPIQYLNAAKVACQTNVADIKSIFPKTQDR</u>
mNTase	322	<u>GSA-FYAFSYYYDRAADTHLIDYE</u> - <u>KGGVLKVEDFERKAREVCD</u> - <u>NLGSSFSSGSP</u> - - -
YGDase	354	<u>ESNDIYIFSYFYDRTRPLGMP</u> <u>LSFTLNE</u> <u>LDLARI</u> <u>VCKGEETWNSVFSGIAGS</u> - - - <u>LDEL</u>
peaNTase	388	<u>NVASVVCMDLIYQYVLLVDGGFGLDPLQKITSGKEIEYQDAI</u> <u>VEAAWPLGNAVEAISA</u> <u>LPK</u>
potapyrase	389	<u>NI-PYLCMDLIYEYTL</u> <u>LLVDGGFGLNPHKEITVI</u> <u>HDVQYKNYLVGAAWPLGCAIDLVSS</u> <u>TN</u>
mNTase	374	- - - <u>FLCMDLTYITALLKDG</u> <u>LGF</u> <u>AERHPLTAHKE</u> <u>SEQHRDWLGLG</u> <u>HLSPAPVSGHHQLR</u>
YGDase	411	<u>ESDSHFCLDLSFQVSL</u> <u>LHTGYDIP</u> <u>LQRELRTGKKIANKE</u> - - - <u>IGWCLGASLP</u> <u>LLKADNW</u>
peaNTase	448	<u>FERLMYFV</u>
potapyrase	448	<u>KIRVASS</u> *
mNTase	430	<u>PSSTSEACISEPVFSQEGVDSETFSDLSGKAWP</u> <u>ETR</u> *
YGDase	467	<u>KCKIQSA</u>

FIG. 2C



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

10/46

ACRI														
CD39	1	VKYGIVL	DAGSSH	TS	LYIYKW	-----	PAEKEND	TGV	-----	VHQVEE	CRVK-GPGIS			
ratCD39	1	VKYGIVL	DAGSSH	TN	LYIYKW	-----	PAEKEND	TGV	-----	VQLLEE	CQVK-GPGIS			
CD39L1	1	LKYGIVL	DAGSSH	TS	MFIIYKW	-----	PADKEND	TGI	-----	VGQHSS	CDVP-GGGIS			
chiATPase	1	FKYGIVL	DAGSSH	TA	VFIYKW	-----	PADKEND	TGV	-----	VSEHSM	CDVE-GPGIS			
peaNTPase	1	SSYAVVF	DAGSTG	SR	IHVYHF	-----	NQ-NLDL	LHIGKGV	EYNN	-----	KITPGLS			
potRRORP1	1	EHYAVIF	DAGSTG	SR	VHVFRF	-----	DE-KLGL	LPIGN	NI	EYFM	-----	ATEPGLS		
YGDA1	1	HKYVIMI	DAGSTG	SR	VHIYKF	-----	DVCTSP	-----	PTLLD	EKFD	-----	MLEPGLS		
mNTPase	1	TFYGYMF	DAGSTG	TR	IHVYTF	-----	VQKTAG	QLPFL	EG	E	IFD	-----	SVKPGLS	
hCD39L2	1	-----	-----	-----	-----	-----	-----	-----	-----	FK	-----	ALKPGLS		
celegans	1	IKYGVIC	DAGSSG	TR	LFVYTL	KPLSGGL	-----	TNIDT	-----	L	-----	IHESEP	VVKKVT	PGLS
y71KD	1	DRFGIVI	DAGSSG	SR	IHVFKW	QDTESSL	HATNQD	SQSI	LQSV	PHIHQ	EKDW	TFKLN	PGLS	

FIG. 3A



ACR II

CD39	47	K <u>F</u> -VQVNEIGI-YLTDCMERAREV <u>I</u> PR--S-QHQETPVYLGATAGMRLLRMES <u>EE</u> LAD	
ratCD39	47	KY-AQKTDEIAA-YLAECMKMSTERIPA--SKQHQTTPVYLGATAGMRLLRMESKQ <u>S</u> AD	
CD39L1	47	SY-ADNPSGASQ-SLVGCLEQALQDVPK--ER-HAGTPLYLGATAGMRLLNLTNPE <u>A</u> ST	
chiATPase	47	SY-SSKPPAAGK-SLEHCLSQAMRDVPK--EK-HADTPLYLGATAGMRLLTIADPP <u>S</u> QT	
peaNTPase	46	SY-ANNPEQA <u>A</u> KS-LIPLLEQAEDVVP--DDLQPKTPVRLGATAGRLLN--GDA- <u>S</u> E	
potRROP1	46	SY-AEDPKAA <u>A</u> NS-LEPLLDGAE <u>G</u> VVP--QELQSETPLELGATAGRLMLK--GDA-A <u>E</u>	
YGDA1	44	SFDTDSV-GA <u>A</u> NS-LDPLLLKVAMNYVPI--KARSCTPVAVKATAGRLLL--GDAK <u>S</u> S	
mNTPase	46	AF-VDQPKQGAET-VQELLEVAKDSIPRSHWE--R--TPVVLKATAGRLLL--PEQKA <u>Q</u>	
hCD39L2	10	AY-ADDVEKSAQ <u>G</u> -IRELLDVAKQDIP--FDSGRP-TPLVLKATAGRLLL--PGEKA <u>Q</u>	
celegans	51	SFG-DKPEQVVE-YLTPLLRFAEEHIPPYEQLGE--TDLLIFFATAGMRLL--PEAQK <u>D</u>	
y71KD	61	SFE-KKPPQDAYKSHIKPLLDFAKNIIPESHWSS--CPVFIQATAGMRLL--PQDI <u>Q</u> S	

FIG. 3B



ACR III

CD39	101	<u>R</u> <u>V</u> <u>L</u> <u>D</u> <u>V</u> <u>V</u> <u>E</u> <u>R</u> <u>S</u> <u>L</u> <u>S</u> <u>N</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>Q</u> <u>G</u> <u>A</u> <u>R</u> <u>I</u> <u>I</u> <u>T</u>	<u>G</u> <u>Q</u> <u>E</u> <u>E</u> <u>G</u> <u>A</u> <u>Y</u> <u>G</u> <u>W</u> <u>I</u> <u>T</u> <u>I</u> <u>N</u> <u>Y</u> <u>L</u> <u>L</u> <u>G</u> <u>K</u> <u>F</u> <u>S</u> <u>Q</u> <u>K</u> <u>T</u> <u>R</u> <u>W</u> <u>F</u> <u>S</u> <u>I</u> <u>V</u> <u>P</u>
ratCD39	101	<u>E</u> <u>V</u> <u>L</u> <u>A</u> <u>A</u> <u>V</u> <u>S</u> <u>R</u> <u>S</u> <u>L</u> <u>K</u> <u>S</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>Q</u> <u>G</u> <u>A</u> <u>K</u> <u>I</u> <u>I</u> <u>T</u>	<u>G</u> <u>Q</u> <u>E</u> <u>E</u> <u>G</u> <u>A</u> <u>Y</u> <u>G</u> <u>W</u> <u>I</u> <u>T</u> <u>I</u> <u>N</u> <u>Y</u> <u>L</u> <u>L</u> <u>G</u> <u>R</u> <u>F</u> <u>T</u> <u>Q</u> <u>E</u> <u>Q</u> <u>S</u> <u>W</u> <u>L</u> <u>N</u> <u>F</u> <u>I</u> <u>S</u>
CD39L1	101	<u>S</u> <u>V</u> <u>L</u> <u>M</u> <u>A</u> <u>V</u> <u>T</u> <u>H</u> <u>T</u> <u>L</u> <u>T</u> <u>Q</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>R</u> <u>G</u> <u>A</u> <u>R</u> <u>I</u> <u>L</u> <u>S</u>	<u>G</u> <u>Q</u> <u>E</u> <u>E</u> <u>G</u> <u>V</u> <u>F</u> <u>G</u> <u>W</u> <u>V</u> <u>T</u> <u>A</u> <u>N</u> <u>Y</u> <u>L</u> <u>L</u> <u>E</u> <u>N</u> <u>F</u> <u>I</u> - <u>K</u> <u>Y</u> <u>G</u> <u>W</u> <u>V</u> <u>G</u> - - - <u>R</u>
chiATPase	101	- <u>C</u> <u>L</u> <u>S</u> <u>A</u> <u>V</u> <u>M</u> <u>A</u> <u>T</u> <u>L</u> <u>K</u> <u>S</u> - <u>Y</u> <u>P</u> <u>F</u> - - - - <u>D</u> <u>F</u> <u>G</u> <u>G</u> <u>A</u> <u>K</u> <u>I</u> <u>L</u> <u>S</u>	<u>G</u> <u>E</u> <u>E</u> <u>E</u> <u>G</u> <u>V</u> <u>F</u> <u>G</u> <u>W</u> <u>I</u> <u>T</u> <u>A</u> <u>N</u> <u>Y</u> <u>L</u> <u>L</u> <u>E</u> <u>N</u> <u>F</u> <u>I</u> - <u>K</u> <u>R</u> <u>G</u> <u>W</u> <u>L</u> <u>G</u> - - - <u>E</u>
peaNTPase	97	<u>K</u> <u>I</u> <u>L</u> <u>Q</u> <u>S</u> <u>V</u> <u>R</u> <u>D</u> <u>M</u> <u>L</u> <u>S</u> <u>N</u> <u>R</u> <u>S</u> <u>T</u> <u>F</u> <u>N</u> - <u>V</u> <u>Q</u> <u>P</u> <u>D</u> - <u>A</u> - <u>V</u> <u>S</u> <u>I</u> <u>I</u> <u>D</u> <u>G</u>	<u>T</u> <u>Q</u> <u>E</u> <u>Q</u> <u>S</u> <u>Y</u> <u>L</u> <u>W</u> <u>V</u> <u>T</u> <u>V</u> <u>N</u> <u>Y</u> <u>A</u> <u>L</u> <u>G</u> <u>N</u> - - - - - <u>L</u> - - - - <u>G</u>
potRRP1	97	<u>K</u> <u>I</u> <u>L</u> <u>Q</u> <u>A</u> <u>V</u> <u>R</u> <u>N</u> <u>L</u> <u>V</u> <u>K</u> <u>N</u> <u>Q</u> <u>S</u> <u>T</u> <u>F</u> <u>H</u> - - <u>S</u> <u>K</u> <u>D</u> - <u>Q</u> <u>W</u> <u>V</u> <u>T</u> <u>I</u> <u>L</u> <u>D</u> <u>G</u>	<u>T</u> <u>Q</u> <u>E</u> <u>G</u> <u>S</u> <u>Y</u> <u>M</u> <u>W</u> <u>A</u> <u>A</u> <u>I</u> <u>N</u> <u>Y</u> <u>L</u> <u>L</u> <u>G</u> <u>N</u> - - - - - <u>L</u> - - - - <u>G</u>
YGDA1	95	<u>K</u> <u>I</u> <u>L</u> <u>S</u> <u>A</u> <u>V</u> <u>R</u> <u>D</u> <u>H</u> <u>L</u> <u>E</u> <u>K</u> <u>D</u> <u>Y</u> <u>P</u> <u>P</u> <u>P</u> <u>V</u> <u>V</u> <u>E</u> <u>G</u> <u>D</u> - <u>G</u> - <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>G</u> <u>G</u>	<u>D</u> <u>E</u> <u>E</u> <u>G</u> <u>V</u> <u>F</u> <u>A</u> <u>W</u> <u>I</u> <u>T</u> <u>T</u> <u>N</u> <u>Y</u> <u>L</u> <u>L</u> <u>G</u> <u>N</u> - - - - - <u>I</u> <u>G</u> <u>A</u> <u>N</u> <u>G</u>
mNTPase	97	<u>A</u> <u>L</u> <u>L</u> <u>L</u> <u>E</u> <u>V</u> <u>E</u> <u>E</u> <u>I</u> <u>F</u> - <u>K</u> <u>N</u> <u>S</u> <u>P</u> <u>F</u> - <u>L</u> <u>V</u> - <u>P</u> <u>D</u> - <u>G</u> <u>S</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>D</u> <u>G</u>	<u>S</u> <u>Y</u> <u>E</u> <u>G</u> <u>I</u> <u>L</u> <u>A</u> <u>W</u> <u>V</u> <u>T</u> <u>V</u> <u>N</u> <u>F</u> <u>L</u> <u>T</u> <u>G</u> <u>Q</u> - - - - - <u>L</u> <u>H</u> <u>G</u> <u>R</u> <u>G</u>
hCD39L2	61	<u>K</u> <u>L</u> <u>L</u> <u>Q</u> <u>K</u> <u>V</u> <u>K</u> <u>E</u> <u>Y</u> <u>L</u> - <u>K</u> <u>H</u> <u>S</u> <u>P</u> <u>F</u> - <u>L</u> <u>V</u> - <u>G</u> <u>D</u> - <u>D</u> <u>C</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>N</u> <u>G</u>	<u>T</u> <u>D</u> <u>E</u> <u>G</u> <u>V</u> <u>S</u> <u>A</u> <u>W</u> <u>X</u> <u>T</u> <u>I</u> <u>N</u> <u>F</u> <u>L</u> <u>T</u> <u>G</u> <u>S</u> - - - - - <u>L</u> <u>K</u> <u>T</u> <u>P</u> <u>G</u>
celegans	102	<u>A</u> <u>I</u> <u>I</u> <u>K</u> <u>N</u> <u>L</u> <u>Q</u> <u>N</u> <u>G</u> <u>L</u> <u>K</u> <u>S</u> <u>V</u> <u>T</u> <u>A</u> <u>L</u> <u>R</u> <u>V</u> <u>S</u> <u>D</u> - - - <u>S</u> <u>N</u> <u>I</u> <u>R</u> <u>I</u> <u>I</u> <u>D</u> <u>G</u>	<u>A</u> <u>W</u> <u>E</u> <u>G</u> <u>I</u> <u>Y</u> <u>S</u> <u>W</u> <u>I</u> <u>A</u> <u>V</u> <u>N</u> <u>I</u> <u>L</u> <u>G</u> <u>R</u> - - - - - <u>F</u> - <u>D</u> - - -
Y71KD	113	<u>S</u> <u>I</u> <u>L</u> <u>D</u> <u>G</u> <u>L</u> <u>C</u> <u>Q</u> <u>G</u> <u>L</u> <u>K</u> <u>H</u> <u>P</u> <u>A</u> <u>E</u> <u>F</u> <u>L</u> <u>V</u> <u>E</u> <u>D</u> <u>C</u> <u>S</u> - <u>A</u> <u>Q</u> <u>I</u> <u>Q</u> <u>V</u> <u>I</u> <u>D</u> <u>G</u>	<u>E</u> <u>T</u> <u>E</u> <u>G</u> <u>L</u> <u>Y</u> <u>G</u> <u>W</u> <u>L</u> <u>G</u> <u>L</u> <u>N</u> <u>Y</u> <u>L</u> <u>Y</u> <u>G</u> <u>H</u> - - - - - <u>F</u> <u>N</u> <u>D</u> <u>Y</u> <u>N</u>

FIG. 3C



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS


Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

13/46

		ACRIV	
CD39	155	<u>YETNNQETFGALD</u>	<u>LGGA</u> <u>STQ</u> <u>VT</u> <u>FV</u> <u>PQ</u> <u>NQ</u>
ratCD39	155	<u>-DSQKQATFGALD</u>	<u>LGGS</u> <u>STQ</u> <u>VT</u> <u>FV</u> <u>PL</u> <u>NQ</u>
CD39L1	152	<u>WFRPRKGTLGAMD</u>	<u>LGGA</u> <u>STQ</u> <u>IT</u> <u>FET</u> <u>TSP</u>
chiATPase	151	<u>WIQSKKKTLGAMD</u>	<u>FGGA</u> <u>STQ</u> <u>IT</u> <u>FET</u> <u>SDAI</u>
peaNTPase	144	<u>KKYTK--TVGVID</u>	<u>LGGS</u> <u>VQ</u> <u>MAY</u> <u>AV</u> <u>SKK</u>
potRROP1	144	<u>KDYKS--TTATID</u>	<u>LGGS</u> <u>VQ</u> <u>MAY</u> <u>AI</u> <u>SNE</u>
YGDA1	146	<u>PKL-P--TAAVFD</u>	<u>LGGS</u> <u>STQ</u> <u>IV</u> <u>FET</u> <u>TFPI</u>
mNTPase	146	<u>QE-----TVGTL</u>	<u>D</u> <u>LGGA</u> <u>STQ</u> <u>IT</u> <u>FL</u> <u>PQ</u> <u>FE</u>
hCD39L2	110	<u>GS-----SVGML</u>	<u>D</u> <u>LGGS</u> <u>STQ</u> <u>IA</u> <u>FL</u> <u>PR</u> <u>VE</u>
celegans	149	<u>KE-NDS-KVGMID</u>	<u>DMGG</u> <u>ASVQ</u> <u>IA</u> <u>FE</u> <u>IA-NE</u>
Y71KD	165	<u>PEVSDHFTFGFMD</u>	<u>DMGG</u> <u>ASTQ</u> <u>IA</u> <u>F--</u> <u>APHDS</u>

FIG. 3D



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS


Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

14/46

```
GTGGGGTCGT ATCCCGCGGG TGGAGGCCGG GGTGGCGCCG GCCGGGGCGG GGGAGCCCAA 60
AAGACCGGCT GCCGCCCTGCT CCCCAGGAAA GGGCACTCGT CTCCGTGGGT GTGGCGGAGC 120
GCGCGGTGCA TGAATGGC TATGTGAATG AAAAAAGTA TCCGTTATGA AACTCCAGA 180
AAAACGAGCT ACATTTTCA GCAGCCGCAG CACGGTCCTT GGCAACAAG G ATG AGA 237
Met Arg
1
AAA ATA TCC AAC CAC GGG AGC CTG CGG GTG GCG AAG GTG GCA TAC CCC 285
Lys Ile Ser Asn His Gly Ser Leu Arg Val Ala Lys Val Ala Tyr Pro
5 10 15
CTG GGG CTG TGT GTG GGC GTG TTC ATC TAT GTT GCC TAC ATC AAG TGG 333
Leu Gly Leu Cys Val Gly Val Phe Ile Tyr Val Ala Tyr Ile Lys Trp
20 25 30
CAC CGG GCC ACC GCC ACC CAG GCC TTC TTC AGC ATC ACC AGG GCA GCC 381
His Arg Ala Thr Ala Thr Gln Ala Phe Phe Ser Ile Thr Arg Ala Ala
35 40 45 50
```

FIG. 4A



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

15/46

CCG GGG GCC CGG TGG GGT CAG CAG GCC CAC AGC CCC CTG GGG ACA GCT	429
Pro Gly Ala Arg Trp Gly Gln Gln Ala His Ser Pro Leu Gly Thr Ala	65
	55
GCA GAC GGG CAC GAG GTC TTC TAC GGG ATC ATG TTT GAT GCA GGA AGC	477
Ala Asp Gly His Glu Val Phe Tyr Gly Ile Met Phe Asp Ala Gly Ser	80
	70
	75
ACT GGC ACC CGA GTA CAC GTC TTC CAG TTC ACC CGG CCC CCC AGA GAA	525
Thr Gly Thr Arg Val His Val Phe Phe Gln Phe Thr Arg Pro Pro Arg Glu	90
	85
	95
ACT CCC ACG TTA ACC CAC GAA ACC TTC AAA GCA GTG AAG CCA GGT CTT	573
Thr Pro Thr Leu Thr His Glu Thr Phe Lys Ala Val Lys Pro Gly Leu	100
	105
	110
TCT GCC TAT GCT GAT GAT GTT GAA AAG AGC GCT CAG GGA ATC CGG GAA	621
Ser Ala Tyr Ala Asp Asp Val Glu Lys Ser Ala Gln Gly Ile Arg Glu	125
	120
	130

FIG. 4B



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

16/46

CTA CTG GAT GTT GCT AAA CAG GAC ATT CCG TTC GAC TTC TGG AAG GCC	669
Leu Leu Asp Val Ala Lys Gln Asp Ile Pro Phe Asp Phe Trp Lys Ala	145
135	
ACC CCT CTG GTC CTC AAG GCC ACA GCT GGC TTA CGC CTG TTA CCT GGA	717
Thr Pro Leu Val 150	
155	
160	
GAA AAG GCC CAG AAG TTA CTG CAG AAG GTG AAA GAA GTA TTT AAA GCA	765
Glu Lys Ala Gln Lys Leu Lys Val Lys Glu Val Phe Lys Ala	175
165	
170	
TCG CCT TTC CTT GTA GGG GAT GAC TGT GTT TCC ATC ATG AAC GGA ACA	813
Ser Pro Phe Leu Val Gly Asp Asp Cys Val Ser Ile Met Asn Gly Thr	190
180	
185	
GAT GAA GGC GTT TCG GCG TGG ATC ACC ATC AAC TTC CTG ACA GGC AGC	861
Asp Glu Gly Val Ser Ala Trp Ile Thr Ile Asn Phe Leu Thr Gly Ser	210
195	
200	
205	
TTG AAA ACT CCA GGA GGG AGC AGC GTG GGC ATG CTG GAC TTG GGC GGA	909
Leu Lys Thr Pro Gly Gly Ser Val Gly Met Leu Asp Leu Gly Gly	225
215	
220	

FIG. 4C





Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

17/46

GGA TCC ACT CAG ATC GCC TTC CTG CCA CGC GTG GAG GGC ACC CTG CAG	957
Gly Ser Thr Gln Ile Ala Phe Leu Pro Arg Val Glu Gly Thr Leu Gln	
230 235 240	
GCC TCC CCA CCC GGC TAC CTG ACG GCA CTG CGG ATG TTT AAC AGG ACC	1005
Ala Ser Pro Pro Gly Tyr Leu Thr Ala Leu Arg Met Phe Asn Arg Thr	
245 250 255	
TAC AAG CTC TAT TCC TAC AGC TAC CTC GGC CTC GGG CTG ATG TCG GCA	1053
Tyr Lys Leu Tyr Ser Tyr Ser Tyr Leu Gly Leu Gly Leu Met Ser Ala	
260 265 270	
CGC CTG GCG ATC CTG GGC GGC GTG GAG GGC CAG CCT GCT AAG GAT GGA	1101
Arg Leu Ala Ile Leu Gly Gly Val Glu Gly Gln Pro Ala Lys Asp Gly	
275 280 285 290	
AAG GAG TTG GTC AGC CCT TGC TTG TCT CCC AGT TTC AAA GGA GAG TGG	1149
Lys Glu Leu Val Ser Pro Cys Leu Ser Pro Ser Phe Lys Gly Glu Trp	
295 300 305	
GAA CAC GCA GAA GTC ACG TAC AGG GTT TCA GGC CAG AAA GCA GCG GCA	1197
Glu His Ala Glu Val Thr Tyr Arg Val Ser Gly Gln Lys Ala Ala Ala	
310 315 320	

FIG. 4D



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

18/46

AGC CTG CAC GAG CTG TGT GCT GCC AGA GTG TCA GAG GTC CTT CAA AAC	1245
Ser Leu His Glu Leu Cys Ala Ala Arg Val Ser Glu Val Leu Gln Asn	
325 330 335	
AGA GTG CAC AGG ACG GAG GAG GAA GTG AAG CAT GTG GAC TTC TAT GCT TTC	1293
Arg Val His Arg Thr Glu Glu Val Lys His Val Asp Phe Tyr Ala Phe	
340 345 350	
TCC TAC TAT TAC GAC CTT GCA GCT GGT GTG GGC CTC ATA GAT GCG GAG	1341
Ser Tyr Tyr Tyr Asp Leu Ala Ala Gly Val Gly Leu Ile Asp Ala Glu	
355 360 365	370
AAG GGA GGC AGC CTG GTG GTG GGG GAC TTC GAG ATC GCA GCC AAG TAC	1389
Lys Gly Gly Ser Leu Val Val Gly Asp Phe Glu Ile Ala Ala Lys Tyr	
375 380 385	
GTG TGT CGG ACC CTG GAG ACA CAG CCG CAG AGC AGC CCC TTC TCA TGC	1437
Val Cys Arg Thr Leu Glu Thr Gln Pro Gln Ser Ser Pro Phe Ser Cys	
390 395 400	
ATG GAC CTC ACC TAC GTC AGC CTG CTA CTC CAG GAG TTC GGC TTT CCC	1485
Met Asp Leu Thr Tyr Val Ser Leu Leu Gln Glu Phe Gly Phe Pro	
405 410 415	

FIG. 4E



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

19/46

AGG AGC AAA GTG CTG AAG CTC ACT CGG AAA ATT GAC AAT GTT GAG ACC	1533
Arg Ser Lys Val Leu Lys Leu Thr Arg Lys Ile Asp Asn Val Glu Thr	
420	425
	430
AGC TGG GCT CTG GGG GCC ATT TTT CAT TAC ATC GAC TCC CTG AAC AGA	1581
Ser Trp Ala Leu Gly Ala Ile Phe His Tyr Ile Asp Ser Leu Asn Arg	
435	440
	445
	450
CAG AAG AGT CCA GCC TCA TAGTGGCCGA GCCATCCCTG TCCCCGTCAG	1629
Gln Lys Ser Pro Ala Ser	
455	
CAGTGTCTGT GTGTCTGCAT AAACCCCTCCT GTCCTGGACG TGA CTTTCATC CTGAGGAGCC	1689
ACAGCACAGG CCGTGCTGGC ACTTTCIGCA CACTGGCTCT GGGACTTGCA GAAGGCCCTGG	1749
TGCTGCCCTG GCATCAGCCT CTTCCAGTCA CATCTGGCCA GAGGGCTGTC TGGACCTGGG	1809
CCCTGCTCAA TGCCACCTGT CTGCCCTGGGC TCCAAGTGGG CAGGACCAGG ACAGAACCCAC	1869
AGGCACACAC TGAGGGGGCA GTGTGGCTCC CTGCCTGTCC CATCCCCATG CCCCCTCCGC	1929

FIG. 4F



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS


Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

20/46

GGGGCTGTGG CTGCTGCTGT GCATGTCCCT GCGATGGGAG TCTTGCTCTCC CAGCCTGTCA 1989  
GTTTCCCTCCC CAGGGCAGAG CTCCTCTTCC TGCAAGAGTC TGGGAGGCGG TGCAGGCTGT 2049  
CCTGGCTGCT CTGGGAAGC CGAGGGACAG CCATAACACC CCCGGACAG TAGGCTGGG 2109  
CGGCACCACT GGGAACTCTG GACTTGAGTG TGTTTGCTCT TCCTTGGGTA TGAATGTGTG 2169  
AGTTCACCCA GAGGCCTGCT CTCCTCACAC ATTGTGTTT TGGGGTTAA TGATGGAGGG 2229  
AGACACCTCT TCATAGACGG CAGGTGCCCA CCTTTCAGGG AGTCTCCCAG CATGGGCGGA 2289  
TGCCGGGCAT GAGCTGCTGT AACTATTG TGGCTGTGCT GCTTGAGTGA CGTCTCTGTC 2349  
GTGTGGGTGC CAAGTGCTTG TGAGAAACT GTGTCTGAG CCCCCTTTC TGGACACCAA 2409  
CTGTGTCCTG TGAATGTATC GCTACTGTGA GCTGTTCCCG CCTAGCCAGG GCCATGTCTT 2469  
AGGTGCAGCT GTGCCACGG TCAGCTGAGC CACAGTCCCA GAACCAAGCT CTCGGTGTCT 2529

FIG. 4G



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS


Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

21/46

CGGGCCACCA	TCCGCCCACC	TCGGGCTGAC	CCCACCTCCT	CCATGGACAG	TGTGAGCCCC	2589
GGGCCGTGCA	TCCTGCTCAG	TGTGGCGTCA	GTGTCGGGGC	TGAGCCCCCTT	GAGCTGCTTC	2649
AGTGAATGTA	CAGTGCCCCG	CACGAGCTGA	ACCTCATGTG	TTCCACTCCC	AATAAAAGGT	2709
TGACAGGGGC	TTCTCCTTCA	AAAAAAAAAA	AAAAAAAAAA	AAAAAAAAAA	AAA	2762

FIG. 4H



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

22/46

FIG. 5A




FIG. 5B





FIG. 5C





Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

23/46

FIG. 5D






FIG. 5E





Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

24/46

```

ACCCACGCGT CTGGCCGCGG GCCGCCTCTG CGGCAGCGCT AGTCGCCTTC TCCGAATCGG 60

CTCCGCACAG CTAGGAGAAA AG ATG TTC ACT GTG CTG ACC CGC CAA CCA TGT 112
Met Phe Thr Val Leu Thr Arg Gln Pro Cys
1 5 10

GAG CAA GCA GGC CTC AAG GCC CTC TAC CGA ACT CCA ACC ATC ATT GCC 160
Glu Gln Ala Gly Leu Lys Ala Leu Tyr Arg Thr Pro Thr Ile Ile Ala
15 20 25

TTG GTG GTC TTG CTT GTG AGT ATT GTG GTA CTT GTG AGT ATC ACT GTC 208
Leu Val Val Leu Leu Val Ser Ile Val Val Leu Val Ser Ile Thr Val
30 35 40

ATC CAG ATC CAC AAG CAA GAG GTC CTC CCT CCA GGA CTG AAG TAT GGT 256
Ile Gln Ile His Lys Gln Glu Val Leu Pro Pro Gly Leu Lys Tyr Gly
45 50 55

ATT GTG CTG GAT GCC GGG TCT TCA AGA ACC ACA GTC TAC GTG TAT CAA 304
Ile Val Leu Asp Ala Gly Ser Ser Arg Thr Thr Val Tyr Val Tyr Gln
60 65 70
```

FIG. 6A





Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

25/46

TGG CCA GCA GAA AAA GAG AAT AAT ACC GGA GTG GTC AGT CAA ACC TTC	352
Trp Pro Ala Glu Lys Glu Asn Thr Gly Val Ser Gln Thr Phe	90
75	85
AAA TGT AGT GTG AAA GGC TCT GGA ATC TCC AGC TAT GGA AAT AAC CCC	400
Lys Cys Ser Val Lys Gly Ser Gly Ile Ser Ser Tyr Gly Asn Asn Pro	105
95	100
caa gat gtc ccc aga gcc ttt gag gag tgt atg caa aaa gtc aag ggg	448
Gln Asp Val Pro Arg Ala Phe Glu Glu Cys Met Gln Lys Val Lys Gly	120
110	115
CAG GTT CCA TCC CAC CTC CAC GGA TCC ACC CCC ATT CAC CTG GGA GCC	496
Gln Val Pro Ser His Leu His Gly Ser Thr Pro Ile His Leu Gly Ala	135
125	130
ACG GCT GGG ATG CGC TTG CTG AGG TTG CAA AAT GAA ACA GCA GCT AAT	544
Thr Ala Gly Met Arg Leu Leu Arg Leu Gln Asn Glu Thr Ala Ala Asn	150
140	145
GAA GTC CTT GAA AGC ATC CAA AGC TAC TTC AAG TCC CAG CCC TTT GAC	592
Glu Val Leu Glu Ser Ile Gln Ser Tyr Phe Lys Ser Gln Pro Phe Asp	165
155	160
	170

FIG. 6B



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

26/46

TTT	AGG	GGT	GCT	CAA	ATC	ATT	TCT	GGG	CAA	GAA	GGG	GTA	TAT	GGA	640
Phe	Arg	Gly	Ala	Gln	Ile	Ile	Ser	Gly	Gln	Glu	Gly	Val	Tyr	Gly	
				175				180						185	
TGG	ATT	ACA	GCC	AAC	TAT	TTA	ATG	GGA	AAT	TTC	CTG	GAG	AAG	AAC	CTG
Trp	Ile	Thr	Ala	Asn	Tyr	Leu	Met	Gly	Asn	Phe	Leu	Glu	Lys	Asn	Leu
				190				195					200		688
TGG	CAC	ATG	TGG	GTG	CAC	CCG	CAT	GGA	GTG	GAA	ACC	ACG	GGT	GCC	CTG
Trp	His	Met	Trp	Val	His	Pro	His	Gly	Val	Glu	Thr	Thr	Gly	Ala	Leu
				205			210					215			736
GAC	TTA	GGT	GGT	GCC	TCC	ACC	CAA	ATA	TCC	TTC	GTG	GCA	GGA	GAG	AAG
Asp	Leu	Gly	Gly	Ala	Ser	Thr	Gln	Ile	Ser	Phe	Val	Ala	Gly	Glu	Lys
				220		225					230				
ATG	GAT	CTG	AAC	ACC	AGC	GAC	ATC	ATG	CAG	GTG	TCC	CTG	TAT	GGC	TAC
Met	Asp	Leu	Asn	Thr	Ser	Asp	Ile	Met	Gln	Val	Ser	Leu	Tyr	Gly	Tyr
				235		240				245					250
GTA	TAC	ACG	CTC	TAC	ACA	CAC	AGC	ATC	CAG	TTC	TAT	GGC	CGG	AAT	GAG
Val	Tyr	Thr	Leu	Tyr	Thr	His	Ser	Phe	Gln	Cys	Tyr	Gly	Arg	Asn	Glu
				255					260						265

FIG. 6C



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

27/46

GCT GAG AAG AAG TTT CTG GCA ATG CTC CTG CAG AAT TCT CCT ACC AAA	928
Ala Glu Lys Lys Phe Leu Ala Met Leu Leu Gln Asn Ser Pro Thr Lys	
270 275 280	
AAC CAT CTC ACC AAT CCC TGT TAC CCT CGG GAT TAT AGC ATC AGC TTC	976
Asn His Leu Thr Asn Pro Cys Tyr Pro Arg Asp Tyr Ser Ile Ser Phe	
285 290 295	
ACC ATG GGC CAT GTA TTT GAT AGC CTG TGC ACT GTG GAC CAG AGG CCA	1024
Thr Met Gly His Val Phe Asp Ser Leu Cys Thr Val Asp Gln Arg Pro	
300 305 310	
GAA AGT TAT AAC CCC AAT GAT GTC ATC ACT TTT GAA GGA ACT GGG GAC	1072
Glu Ser Tyr Asn Pro Asn Asp Val Ile Thr Phe Glu Gly Thr Gly Asp	
315 320 325 330	
CCA TCT CTG TGT AAG GAG AAG GTG GCT TCC ATA TTT GAC TTC AAA GCT	1120
Pro Ser Leu Cys Lys Glu Lys Val Ala Ser Ile Phe Asp Phe Lys Ala	
335 340 345	
TGC CAT GAT CAA GAA ACC ACC TGT TCT TTT GAT GGG GTT TAT CAG CCA AAG	1168
Cys His Asp Gln Glu Thr Cys Ser Phe Asp Gly Val Tyr Gln Pro Lys	
350 355 360	

FIG. 6D



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

28/46

ATT AAA GGG CCA TTT GTG GCT TTT GCA GGA TTC TAC TAC ACA GCC AGT	1216
Ile Lys Gly Pro Phe Val Ala Phe Phe Gly Phe Tyr Tyr Thr Ala Ser	
365 370 375	
GCT TTA AAT CTT TCA GGT AGC TTT TCC CTG GAC ACC TTC AAC TCC AGC	1264
Ala Leu Asn Leu Ser Gly Ser Phe Ser Ser Leu Asp Thr Phe Asn Ser Ser	
380 385 390	
ACC TGG AAT TTC TGC TCA CAG AAT TGG AGT CAG CTC CCA CTG CTG CTC	1312
Thr Trp Asn Phe Cys Ser Ser Gln Asn Trp Ser Gln Leu Pro Leu Leu	
395 400 405 410	
CCC AAA TTT GAT GAG GTA TAT GCC CGC TCT TAC TGC TTC TCA GCC AAC	1360
Pro Lys Phe Asp Glu Val Tyr Ala Arg Ser Tyr Cys Phe Ser Ala Asn	
415 420 425	
TAC ATC TAC CAC TTG TTT GTG AAC GGT TAC AAA TTC ACA GAG GAG ACT	1408
Tyr Ile Tyr His Leu Phe Phe Val Asn Gly Tyr Lys Phe Thr Glu Glu Thr	
430 435 440	
TGG CCC CAA ATA CAC TTT GAA AAA GAA GTG GGG AAT AGC AGC ATA GCC	1456
Trp Pro Gln Ile His Phe Glu Lys Glu Val Gly Asn Ser Ser Ile Ala	
445 450 455	

FIG. 6E



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

29/46

TGG TCT CTT GGC TAC ATG CTC AGC CTG ACC AAC CAG ATC CCA GCT GAA	1504
Trp Ser Leu Gly Tyr Met Leu Ser Leu Thr Asn Gln Ile Pro Ala Glu	
460	470
AGC CCT CTG ATC CGT CTG CCC ATA GAA CCA CCT GTC TTT GTG GGC ACC	1552
Ser Pro Leu Ile Arg Leu Pro Ile Glu Pro Pro Val Phe Val Gly Thr	
475	480
	485
	490
CTC GCT TTC TTC ACA GTG GCA GCC TTG CTG TGT CTG GCA TTT CTT GCA	1600
Leu Ala Phe Phe Thr Val Ala Ala Leu Leu Cys Leu Ala Phe Leu Ala	
495	500
	505
TAC CTG TGT TCA GCA ACC AGA AGA AAG AGG CAC TCC GAG CAT GCC TTT	1648
Tyr Leu Cys Ser Ala Thr Arg Arg Lys Arg His Ser Glu His Ala Phe	
510	515
	520
GAC CAT GCA GTG GAT TCT GAC TGAGCCTTCA AAGCAGCTCC TGGAGTCCAA	1699
Asp His Ala Val Asp Ser Asp	
525	
TGGCTGCTTA GAGTCAGCCT GGGTGGCACC AGGCAATGCA GGTGAAGTGG CTGCCTTCAG	1759

FIG. 6F



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

30/46

GAAATACAAC TAACTAAAAT CAAACACCTA GGTCACGTGC CTCTCAAATA CTGATTTCTG 1819  
CCACAGCACC TCTTGAGGCA TCCCTTGGCT ATTCTGTGCA TATTGTTCTT CAGAGACCTC 1879  
ACTACCCACA TGCTGATCTA TTGGGGAACA GAGAAGAGAC AGGCCACTAA GGTGAGGCTC 1939  
TTTATATTAA GTTCCCCAGA GGAAGAGTAA GTTGAGAAGG TATCAGTTTA ATGTTGAAGA 1999  
ATTGACCTCA GGGCTCAGTT TCCATTTCCTC TCCCTCAGTA TTCCTCCTGG CAAGATACCC 2059  
ATTAAGCATT TCGCCAATCA GAATCTCATTTTATAGTTTT TCCCATTTGGT CTTTAACTAA 2119  
GACTTTCTTG TAGCAATCTC GTAAGCAGTG AACCCCTCA GATCAGTAGA ATATAGTATC 2179  
TGGGGGAGAA GACTTACTTC CTTCAGGGCA GCAGCCACAG CCAGGCTTCT GTCATACAGG 2239  
TAGATCCCGA AGCACAGAGA CATAAAAAG GTCTCCCAGA AAACATATAGA CCATTCTCCA 2299  
AGTGGAATTC CCACTTAGGG CTCTGGTCAC TAGATTGCAA CCTGTGTGTT TGTATCATC 2359  
CTCATCTCAC CATTGTATTG CTATGCCCTC CCATAAAAC ACATTGATCC CTAGCAAGAT 2419

FIG. 6G



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

31/46

TATTGCATTTC CAGATTTTAC TGCCTTTGCT AGGCTTTTGC TTAGCAAAGG GCTGACTTTC 2479  
CATTGTTATC ATGGTGTATA TATTTTGTGTC ACCATTCCCA CAAGTATACT TGATGTTGTC 2539  
ATAGAACGAA CATCCTACTC TATGATTTAC TAACCAATTA CTTTCCCAGA TCATAGACCT 2599  
CTCTGCATAG TAGTCATAGG TCTTGACTTT GGGGAAAGAA AAGGAAGCTG CAGGAATATT 2659  
TATCTCCAAA GTCGAATGAG AAAGAACTCC AGCAAATCCA ATGGCTACAA ACTAAAAATC 2719  
AGCATTTATT CATATTGCTG TTTCTTAGCT GAATATGGAA TAAAGAACTA TTATTTTATT 2779  
TTGAAAAAAA AAAAAAAA 2797

FIG. 6H



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

32/46

GGCGCGCGGT TTTCCTTGTT CCTGGTCAAC AAAGAAATGT GGAGTGCTTT GGCTGAATCC 60  
TCATACAGAC AAGATCATTA TGGTGCTGTT AGGTAGGACT TGTATCCAGA TGTAGGTTG 120  
AAAAAGTGAT ATAATAAAGG AACCAAGGAG AAAATTCAGA AGGAAAGAAA AAATTGCCTC 180  
TGCAGGTGTG CGAGCAGGAT TGCTTCTGCA ACAAAGCCT CCACCCAGCC ACATCTTGGG 240  
AAAAGA ATG GCC ACT TCT TGG GGC ACA GTC TTT TTC ATG CTG GTG GTA 288  
Met Ala Thr Ser Trp Gly Thr Val Phe Phe Met Leu Val Val  
1 5 10  
TCC TGT GTT TGC AGC GCT GTC TCC CAC AGG AAC CAG CAG ACT TGG TTT 336  
Ser Cys Val Cys Ser Ala Val Ser His Arg Asn Gln Gln Thr Trp Phe  
15 20 25 30  
GAG GGT ATC TTC CTG TCT TCC ATG TGC CCC ATC AAT GTC AGC GCC AGC 384  
Glu Gly Ile Phe Leu Ser Ser Met Cys Pro Ile Asn Val Ser Ala Ser  
35 40 45  
ACC TTG TAT GGA ATT ATG TTT GAT GCA GGG AGC ACT GGA ACT CGA ATT 432  
Thr Leu Tyr Gly Ile Met Phe Asp Ala Gly Ser Thr Gly Thr Arg Ile  
50 55 60

FIG. 7A





Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

33/46

CAT GTT TAC ACC TTT GTG CAG AAA ATG CCA GGA CAG CTT CCA ATT CTA	480
His Val Tyr Thr Phe Val Gln Lys Met Pro Gly Gln Leu Pro Ile Leu	75
	70
	65
GAA GGG GAA GTT TTT GAT TCT GTG AAG CCA GGA CTT TCT GCT TTT GTA	528
Glu Gly Glu Val Phe Asp Ser Val Lys Pro Gly Leu Ser Ala Phe Val	90
	85
	80
GAT CAA CCT AAG CAG GGT GCT GAG ACC GTT CAA GGG CTC TTA GAG GTG	576
Asp Gln Pro Lys Gln Gly Ala Glu Thr Val Gln Gly Leu Leu Glu Val	100
	95
	100
	105
GCC AAA GAC TCA ATC CCC CGA AGT CAC TGG AAA AAG ACC CCA GTG GTC	624
Ala Lys Asp Ser Ile Pro Arg Ser His Trp Lys Lys Thr Pro Val Val	115
	120
	125
CTA AAG GCA ACA GCA GGA CTA CGC TTA CTG CCA GAA CAC AAA GCC AAG	672
Leu Lys Ala Thr Ala Gly Leu Arg Leu Leu Pro Glu His Lys Ala Lys	130
	135
	140
GCT CTG CTC TTT GAG GTA AAG GAG ATC TTC AGG AAG TCA CCT TTC CTG	720
Ala Leu Leu Phe Glu Val Lys Glu Ile Phe Arg Lys Ser Pro Phe Leu	145
	150
	155

FIG. 7B



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

34/46

GTA CCA AAG GGC AGT GTT AGC ATC ATG GAT GGA TCC GAC GAA GGC ATA	768
Val Pro Lys Gly Ser Val Ser Ile Met Asp Gly Ser Asp Glu Gly Ile	
160 165 170	
TTA GCT TGG GTT ACT GTG AAT TTT CTG ACA GGT CAG CTG CAT GGC CAC	816
Leu Ala Trp Val Thr Val Asn Phe Leu Thr Gly Gln Leu His Gly His	
175 180 185 190	
AGA CAG GAG ACT GTG GGG ACC TTG GAC CTA GGG GGA GCC TCC ACC CAA	864
Arg Gln Glu Thr Val Gly Thr Leu Asp Leu Gly Gly Ala Ser Thr Gln	
195 200 205	
ATC ACG TTC CTG CCC CAG TTT GAG AAA ACT CTG GAA CAA ACT CCT AGG	912
Ile Thr Phe Leu Pro Gln Phe Glu Lys Thr Thr Leu Glu Gln Thr Pro Arg	
210 215 220	
GGC TAC CTC ACT TCC TTT GAG ATG TTT AAC AGC ACT TAT AAG CTC TAT	960
Gly Tyr Leu Thr Ser Phe Glu Met Phe Asn Ser Thr Tyr Lys Leu Tyr	
225 230 235	
ACA CAT AGT TAC TTG GGA TTT GGA TTG AAA GCT GCA AGA CTA GCA ACC	1008
Thr His Ser Tyr Leu Gly Phe Gly Leu Lys Ala Ala Arg Leu Ala Thr	
240 245 250	

FIG. 7C



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

35/46

CTG GGA GCC CTG GAG ACA GAA GGG ACT GAT GGG CAC ACT TTC CGG AGT	1056
Leu Gly Ala Leu Glu Thr Trp Leu Glu Gly Thr Asp Gly His Thr Phe Arg Ser	255
260	265
GCC TGT TTA CCG AGA TGG TTG GAA GCA GAG TGG ATC TTT GGG GGT GTG	1104
Ala Cys Leu Pro Arg Trp Trp Leu Glu Ala Glu Trp Ile Phe Gly Gly Val	275
280	285
AAA TAC CAG TAT GGT GGC AAC CAA GAA GGG GAG GTG GGC TTT GAG CCC	1152
Lys Tyr Gln Tyr Gly Glu Asn Gln Glu Gly Glu Val Gly Phe Glu Pro	290
295	300
TGC TAT GCC GAA GTG CTG AGG GTG GTA CGA GGA AAA CTT CAC CAG CCA	1200
Cys Tyr Ala Glu Val Leu Arg Val Val Arg Gly Lys Leu His Gln Pro	305
310	315
GAG GAG GTC CAG AGA GGT TCC TTC TAT GCT TTC TCT TAC TAT TAT GAC	1248
Glu Glu Val Gln Arg Gly Ser Phe Tyr Ala Phe Ser Tyr Tyr Tyr Asp	320
325	330
CGA GCT GTT GAC ACA GAC ATG ATT GAT TAT GAA AAG GGG GGT ATT TTA	1296
Arg Ala Val Asp Thr Asp Met Ile Asp Tyr Glu Lys Gly Gly Ile Leu	335
340	345
	350

FIG. 7D



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

36/46

AAA GTT GAA GAT TTT GAA AGA AAA GCC AGG GAA GTG TGT GAT AAC TTG	1344
Lys Val Glu Asp Phe Glu Arg Lys Ala Arg Glu Val Cys Asp Asn Leu	
355 360 365	
GAA AAC TTC ACC TCA GGC AGT CCT TTC CTG TGC ATG GAT CTC AGC TAC	1392
Glu Asn Phe Thr Ser Gly Ser Pro Phe Leu Cys Met Asp Leu Ser Tyr	
370 375 380	
ATC ACA GCC CTG TTA AAG GAT GGC TTT GGC TTT GCA GAC AGC ACA GTC	1440
Ile Thr Ala Leu Leu Lys Asp Gly Phe Gly Phe Ala Asp Ser Thr Val	
385 390 395	
TTA CAG CTC ACA AAG AAA GTG AAC ATA GAG ACG GGC TGG GCC TTG	1488
Leu Gln Leu Thr Lys Lys Val Asn Asn Ile Glu Thr Gly Trp Ala Leu	
400 405 410	
GGG GCC ACC TTT CAC CTG TTG CAG TCT CTG GGC ATC TCC CAT	1530
Gly Ala Thr Phe His Leu Leu Gln Ser Leu Gly Ile Ser His	
415 420 425	
TGAGGCCACG TACTTCCTTG GAGACCTGCA TTGGCCAACA CCTTTTAAAG GGGAGGAGAG	1590

FIG. 7E



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

37/46

AGCACTTAGT TTCTGAACTA GTCTGGGACA TCCTGGACTT GAGCCTAGAG ATTAGGTTT 1650  
AATTAAATTT ACACATCTAA TGTGAACTGC TGCCTAACCA CTCAGAGTA CACAGCTGGC 1710  
ACCAGAGCAT CACAGAGAGC CCTGTGAGCC AAAAAGTATA GTTTTGAAC TTAACCTTGG 1770  
AGTGAGAGCC CAGGGACAGG TCCCTGGAAA CCAAAGAAAA ATCGCATTC AACCCCTTTGA 1830  
GTGCCCTCATT CCACTGAATA TTTAAATTTT CCTCTTAAAT GGTAAGCTGA CTTATTGCAA 1890  
TCCCAAGACC CATCAATATC AGTATTTTTT TCCTCCCCTAT ACAGTGCCCT GCCCACCCCT 1950  
ATCTGCACCC ACCTCCCCTG AAAAGAGAG AAAAAAAAAA 1998

FIG. 7F



CD39L2	1	MKKGIRYETSRKTSYIFQQPQHGPWQTRMRKISNHGSLRVAKVAYPLGLCVGVFIYVAY <del>TH</del>
CD39L4	1	- MATSWG
CD39L1	1	- -
CD39L3	1	- - - - - - - - - - - - - - - - - MFTVLTRQPCEQA <u>G</u> L
CD39	1	- - - - - - - - - - - - - - - - - MEDTKE

		ACRI
CD39L2	61	<div> <div> K W H R A T A T Q A F F S I T R A A P G A R W G Q Q A H - S P L G T A A D G H E V F Y G I M F </div> <div> D A G S T G T R </div> </div>
CD39L4	7	<div> <div> T V F F M L V V S C V C S A V S H R N Q Q T W F E G I F L S S M C P I N V S A S T L Y G I M F </div> <div> D A G S T G T R </div> </div>
CD39L1	1	<div> <div> - - - M A G K V R S L L P P L L A A G L A G L L L C V P T R D V R E P A L K Y G I V L </div> <div> D A G S S H T S M F I Y K </div> </div>
CD39L3	16	<div> <div> K A L Y R T P T I A L V V L V S I V V L V S I T V I Q I H K Q E V L - P P G L K Y G I V L </div> <div> D A G S S R T T V Y Y Y Q </div> </div>
CD39	7	<div> <div> S N V K T F C S K N I L A I L G F S S I A V I A L L A V G L T Q N K A L P E N V K Y G I V L </div> <div> D A G S S H T S L Y I Y K </div> </div>

	CD39L2	120	FT - RPPRETPTLT <u>HE</u> <u>TF</u> <u>KA</u> <u>VK</u> - <u>PG</u> <u>LS</u> <u>AY</u> <u>AD</u> <u>DD</u> <u>VE</u> <u>KS</u> <u>AQ</u> <u>GI</u> <u>RE</u> <u>LL</u> <u>DV</u> <u>AK</u> <u>QD</u> <u>IP</u> <u>FD</u> <u>FW</u> <u>KA</u> <u>TP</u> <u>PL</u>
	CD39L4	67	<u>FV</u> <u>QK</u> <u>MP</u> <u>GG</u> <u>QL</u> <u>PI</u> <u>LE</u> <u>GE</u> <u>VF</u> <u>DS</u> <u>VK</u> - <u>PG</u> <u>LS</u> <u>AF</u> <u>VD</u> <u>QPK</u> <u>QGA</u> <u>ETV</u> <u>QG</u> <u>LL</u> <u>EV</u> <u>AK</u> <u>DS</u> <u>IP</u> <u>RS</u> <u>HW</u> <u>KK</u> <u>TP</u> <u>V</u>
	CD39L1	58	<u>WPA</u> <u>D</u> <u>KE</u> <u>ND</u> <u>TI</u> <u>VG</u> <u>QH</u> <u>SS</u> <u>CD</u> <u>VP</u> <u>GG</u> <u>ISS</u> <u>Y</u> <u>AD</u> <u>NP</u> <u>SG</u> <u>AS</u> <u>QL</u> <u>VG</u> <u>CL</u> <u>EQ</u> <u>AL</u> <u>QD</u> <u>VP</u> <u>KE</u> <u>RH</u> <u>AG</u> <u>TP</u> <u>PL</u>
	CD39L3	75	<u>WPA</u> <u>E</u> <u>KE</u> <u>NN</u> <u>TG</u> <u>VV</u> <u>SQ</u> <u>TF</u> <u>KC</u> <u>SV</u> <u>KG</u> <u>SG</u> <u>ISS</u> <u>Y</u> <u>GN</u> <u>NP</u> <u>QD</u> <u>VP</u> <u>RA</u> <u>FE</u> <u>EC</u> <u>MQ</u> <u>KV</u> <u>KG</u> <u>QV</u> <u>PS</u> <u>HL</u> <u>HG</u> <u>ST</u> <u>PI</u>
	CD39	67	<u>WPA</u> <u>E</u> <u>KE</u> <u>ND</u> <u>TG</u> <u>VV</u> <u>HQ</u> <u>VE</u> <u>EC</u> <u>RV</u> <u>KG</u> <u>GP</u> <u>GIS</u> <u>KF</u> <u>VQ</u> <u>KV</u> <u>NE</u> <u>IG</u> <u>IY</u> <u>LT</u> <u>DC</u> <u>ME</u> <u>RA</u> <u>RE</u> <u>VI</u> <u>PR</u> <u>SQ</u> <u>HQ</u> <u>ET</u> <u>TP</u> <u>V</u>


FIG. 8A

Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCLEIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

39/46



CD39L2	ACR II									
	178.	VLKATAGLRLL	---	PGEKAQKLLQKVK	EVFKAS	PFLVGGDDCV	SIMN	GTDEGV	SAWITIN	
	CD39L4	126	VLKATAGLRLL	---	PEHKAKALLFEVKE	IFRKSPFLVP	PKGSVIMD	GSDEGI	LAWVTN	F
	CD39L1	118	YLGATAGMRLL	NLTNPEASTSVLM	AVTHLTQY	PF--	DFRGARILS	QEEGV	FGWVTAN	Y
	CD39L3	135	HLGATAGMRLL	RLQNETAANEVLES	IQSYFKSQ	PF--	DFRGAQIIS	QEEGV	YGWITAN	Y
CD39	ACR III									
	127	YLGATAGMRLL	RMESSEELADR	VLDVVERSLS	NYPF--	DFQGARIIT	QEEGA	YGWITIN	Y	
	ACR IV									
	CD39L2	235	LTGSL	---	KTPGGSSVGM	LDLGGGSTQ	IAFLPR	VEGTLQAS	PPGYLTALRM	
	CD39L4	183	LTGQL	---	HGHRQETVGT	LDLGGASTQ	ITFLPQ	EKTELT	QTPRGYLTSEFEM	
CD39L1	176	LENF	IKYGVGRWF	--	RPR-KGTLGAM	DLGGASTQ	ITFETT	SPAEDRA	SE--V-QLHL	
	CD39L3	193	LMGNF	LEKNLWHMWV	--	HPHGVETTGAL	DLGGASTQ	ISFVAGE	KMDLNTSD--IMQVSL	
	CD39	185	LLGKFS	QKTRWFS	IVPYETNNQ	ETFGALDLGGASTQ	VTFVPQ	NQTIESPDN--ALQFRL		
	CD39L2	283	FNRTYK	LYSYSLGLGLMS	ARLAILGGVEG	QPAKDGKEL	VSPCLSP	SFKGEWEHAEVTYR		
	CD39L4	231	FNSTYK	LYTHSYLGGFGLK	AARLATLGA	LETE-GTDGHT	FRSACLPR	WLEAEWIFGGVKYQ		
CD39L1	229	YGQH	YRVYTHSFLCYGRDQ	VLQRL	-ASALQ	----	THGFHP	CWPRGFSTQVLLGDVYQS		
	CD39L3	248	YGYV	YTYTHSFCYGRNEA	EKKFL-AMLLQNS	PTKNHLLTNPC	YPRDYSISFTMGHVFDS			
	CD39	242	YGKD	YNVYTHSFLCYGKDQ	ALWQKL-AKD	IQVASNEI-LRDP	CFHPGYKKVNVNSDLYKT			

FIG. 8B

Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

40/46



CD39L2	343	VSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDFYAFSYYDLAGVGLIDAEGGGS
CD39L4	290	YGGNQEGEVGFEPCEYAEVLRVVRGKLHQPEEVQRGSFYAFSYYDRAVDTDMDIYEKGGI
CD39L1	283	PCTMAQRPNFNSARVSLSGSSDPHLCRDLVSGLSFSSC - PFSRCSFNQVFPVAGN
CD39L3	307	LCTVDQRPESYNPNDVITFEGTGDPSLCKEKVASIFDFKACHDQETCSFDGVYQPKIKGP
CD39	300	PCT - - KRFEMTLPPFQQFEIQGIGNYQQCHQSILELFTSYC - PYSQCAFNGIFLPPLOGD
CD39L2	403	LVVGDFEIAAKYVCRTLETQPQSSPSCMDLTYVSLLLQE - FGFPFRSKVLKLTTRKIDNVE
CD39L4	350	LKVEDFERKAREVCNLENFTSGSPFLCMDLSYITALLKDGFGFADSTVLQLTKKVNNE
CD39L1	342	FV - - - - AFSAFFYTVDFLRTSMGLPVA TLQQLAAAVNCNQ TWAQ - - - - -
CD39L3	367	FV - - - - AFAGFYTTASALNLSGSF - - - - SLDTFNSSTWNFCSQNSQLPLLPKFDEVY
CD39	357	FG - - - - AFSAFYFVMKFLNLT - - - - EKVSQEKVTEMMKKFCAQPWEEIKTSYAGVKEKY
CD39L2	462	TSWALGAI FHYIDS LN RQKSPAS *
CD39L4	410	TG WALGATFHLLQSLGISH
CD39L1	384	- - - - - QLSRGYGFDERAFGGVIFQKKAADTAVGWALGYMLNLTNLI PADPPG
CD39L3	418	ARSYCF SANYIYHLFVNGYKFTTEETWPQIHFEKEVGNSSIAWSLGYMLS LTNQIPAESPL
CD39	409	LSEYCFSGTYILSLLQGYHFTADSWEHIHF IGKIQGSDAGWTLGYMLNLTNMI PAEQP -

FIG. 8C





Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

41/46

CD39L2	485	
CD39L4	429	
CD39L1	432	<u>LR</u> <u>KG</u> <u>TD</u> <u>FS</u> <u>SW</u> <u>VV</u> <u>LL</u> <u>LL</u> <u>FA</u> <u>SAL</u> <u>LAA</u> <u>LV</u> <u>LL</u> <u>LR</u> <u>QV</u> <u>HS</u> <u>AK</u> <u>LP</u> <u>ST</u> <u>I</u> *
CD39L3	478	<u>IR</u> <u>LP</u> <u>IE</u> <u>PP</u> <u>VV</u> <u>GT</u> <u>LA</u> <u>FF</u> <u>TV</u> <u>AA</u> <u>LL</u> <u>CL</u> <u>AF</u> <u>LA</u> <u>YL</u> <u>CS</u> <u>AT</u> <u>RR</u> <u>KR</u> <u>HR</u> <u>SE</u> <u>HA</u> <u>FD</u> <u>HA</u> <u>VD</u> <u>SD</u> *
CD39	468	<u>LS</u> <u>TP</u> <u>LS</u> <u>HS</u> <u>TY</u> <u>VV</u> <u>FL</u> <u>MV</u> <u>LF</u> <u>SL</u> <u>VL</u> <u>FT</u> <u>VA</u> <u>II</u> <u>GL</u> <u>LI</u> <u>IF</u> <u>HK</u> <u>PS</u> <u>YF</u> <u>WK</u> <u>DM</u> <u>V</u> *

FIG. 8D



peaGDP	1	-----M
potapyrase	1	-----MLNQN
CD39L2	1	MKKGIRYETSRKTSYIFQQPQHGPWQTRMRKISNHGSLRVAKVAYPLGLCVGVFIYVAYI
CD39L4	1	-----MATSWG
dNTPase	1	-----MKY EYKLLATDEKPPRRKSSGSPNASSGGRGQPSGL
yGDPase	1	-----KTP E
ACRI		
peaGDP	2	ELLIKLITFLFSMPAITSQQYLGNNL-LTSRKIFLKQEEISSYAVVFFDAGSTGSRIHVY
potapyrase	6	SHFIFIILAI FLV LPLSLLSKNVNAQI-PLRRHLLSHESE--HYAVIFFDAGSTGSRVHVF
CD39L2	61	KWHRATATQAFFSITRAAPGARWGQQA-H-SPLGTAADGHEVFYIGIMFDAGSTGTRVHVF
CD39L4	7	TVFFMLVVSVCVCSAVSHRNQQTWFEI-FLSSMCPINVSASTLYGIMFDAGSTGTRIHVY
dNTPase	37	KISFLCLIIISVILLFVFGFVSENASP-YLARLASKFGYSKVQYAAIIDAGSTGSRVLAY
yGDPase	5	DISILPVNDEPGYLQDSKTEQNYPELADAVKSQTSQTCSEHKYVIMIIDAGSTGSRVHIY

FIG. 9A



Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

43/46

ACR II

peaGDP	61	<u>H</u> <u>F</u> <u>N</u> <u>Q</u> <u>N</u> <u>L</u> <u>D</u> <u>L</u> <u>L</u> <u>H</u> <u>I</u> <u>G</u> <u>K</u> <u>G</u> <u>V</u> <u>E</u> <u>Y</u> <u>N</u> <u>K</u> <u>I</u> <u>T</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>S</u> <u>Y</u> <u>A</u> <u>N</u> <u>N</u> <u>P</u> <u>E</u> <u>Q</u> <u>A</u> <u>A</u> <u>K</u> <u>S</u> <u>L</u> <u>I</u> <u>P</u> <u>L</u> <u>L</u> <u>E</u> <u>Q</u> <u>A</u> <u>E</u> <u>D</u> <u>V</u> <u>V</u> <u>P</u> <u>D</u> <u>D</u> <u>L</u> <u>Q</u> <u>P</u> <u>K</u> <u>T</u> <u>P</u> <u>V</u>
potapyrase	63	<u>R</u> <u>F</u> <u>D</u> <u>E</u> <u>K</u> <u>L</u> <u>G</u> <u>L</u> <u>L</u> <u>P</u> <u>I</u> <u>G</u> <u>N</u> <u>N</u> <u>I</u> <u>E</u> <u>Y</u> <u>F</u> <u>M</u> <u>A</u> <u>T</u> <u>E</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>S</u> <u>Y</u> <u>A</u> <u>E</u> <u>D</u> <u>P</u> <u>K</u> <u>A</u> <u>A</u> <u>N</u> <u>S</u> <u>L</u> <u>E</u> <u>P</u> <u>L</u> <u>L</u> <u>D</u> <u>G</u> <u>A</u> <u>E</u> <u>G</u> <u>V</u> <u>V</u> <u>P</u> <u>Q</u> <u>E</u> <u>L</u> <u>Q</u> <u>S</u> <u>E</u> <u>T</u> <u>P</u> <u>L</u>
CD39L2	119	<u>Q</u> <u>F</u> <u>T</u> <u>-</u> <u>R</u> <u>P</u> <u>P</u> <u>R</u> <u>E</u> <u>T</u> <u>P</u> <u>T</u> <u>L</u> <u>T</u> <u>H</u> <u>E</u> <u>T</u> <u>F</u> <u>K</u> <u>A</u> <u>V</u> <u>K</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>A</u> <u>Y</u> <u>A</u> <u>D</u> <u>D</u> <u>V</u> <u>E</u> <u>K</u> <u>S</u> <u>A</u> <u>Q</u> <u>I</u> <u>R</u> <u>E</u> <u>L</u> <u>L</u> <u>D</u> <u>V</u> <u>A</u> <u>K</u> <u>D</u> <u>I</u> <u>P</u> <u>F</u> <u>D</u> <u>F</u> <u>W</u> <u>K</u> <u>A</u> <u>T</u> <u>P</u> <u>L</u>
CD39L4	66	<u>T</u> <u>F</u> <u>V</u> <u>Q</u> <u>K</u> <u>M</u> <u>P</u> <u>G</u> <u>Q</u> <u>L</u> <u>P</u> <u>I</u> <u>L</u> <u>E</u> <u>G</u> <u>E</u> <u>V</u> <u>F</u> <u>D</u> <u>S</u> <u>V</u> <u>K</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>A</u> <u>F</u> <u>V</u> <u>D</u> <u>Q</u> <u>P</u> <u>K</u> <u>Q</u> <u>G</u> <u>A</u> <u>E</u> <u>T</u> <u>V</u> <u>Q</u> <u>G</u> <u>L</u> <u>L</u> <u>E</u> <u>V</u> <u>A</u> <u>K</u> <u>D</u> <u>S</u> <u>I</u> <u>P</u> <u>R</u> <u>S</u> <u>H</u> <u>W</u> <u>K</u> <u>T</u> <u>P</u> <u>V</u>
dNTPase	96	<u>K</u> <u>F</u> <u>N</u> <u>R</u> <u>S</u> <u>F</u> <u>I</u> <u>D</u> <u>N</u> <u>K</u> <u>L</u> <u>V</u> <u>L</u> <u>Y</u> <u>E</u> <u>E</u> <u>L</u> <u>F</u> <u>K</u> <u>E</u> <u>R</u> <u>K</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>S</u> <u>F</u> <u>A</u> <u>D</u> <u>N</u> <u>P</u> <u>A</u> <u>E</u> <u>G</u> <u>A</u> <u>H</u> <u>S</u> <u>I</u> <u>K</u> <u>L</u> <u>L</u> <u>L</u> <u>D</u> <u>E</u> <u>A</u> <u>R</u> <u>A</u> <u>F</u> <u>I</u> <u>P</u> <u>K</u> <u>E</u> <u>H</u> <u>W</u> <u>S</u> <u>T</u> <u>P</u> <u>L</u>
YGDPas	65	<u>K</u> <u>F</u> <u>D</u> <u>-</u> <u>-</u> <u>V</u> <u>C</u> <u>T</u> <u>S</u> <u>P</u> <u>P</u> <u>T</u> <u>L</u> <u>L</u> <u>D</u> <u>E</u> <u>K</u> <u>F</u> <u>D</u> <u>M</u> <u>L</u> <u>E</u> <u>P</u> <u>G</u> <u>L</u> <u>S</u> <u>S</u> <u>F</u> <u>D</u> <u>T</u> <u>D</u> <u>S</u> <u>V</u> <u>G</u> <u>A</u> <u>A</u> <u>N</u> <u>S</u> <u>L</u> <u>D</u> <u>P</u> <u>L</u> <u>L</u> <u>K</u> <u>V</u> <u>A</u> <u>M</u> <u>N</u> <u>Y</u> <u>V</u> <u>P</u> <u>I</u> <u>K</u> <u>A</u> <u>R</u> <u>S</u> <u>C</u> <u>T</u> <u>P</u> <u>V</u>

ACR II

ACR III

peaGDP	121	<u>R</u> <u>L</u> <u>G</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>N</u> <u>G</u> <u>D</u> <u>A</u> <u>S</u> <u>E</u> <u>K</u> <u>I</u> <u>L</u> <u>Q</u> <u>S</u> <u>V</u> <u>R</u> <u>D</u> <u>M</u> <u>L</u> <u>S</u> <u>N</u> <u>R</u> <u>S</u> <u>T</u> <u>F</u> <u>-</u> <u>N</u> <u>V</u> <u>Q</u> <u>P</u> <u>D</u> <u>A</u> <u>V</u> <u>S</u> <u>I</u> <u>I</u> <u>D</u> <u>G</u> <u>T</u> <u>Q</u> <u>E</u> <u>G</u> <u>S</u> <u>Y</u> <u>L</u> <u>W</u> <u>V</u> <u>T</u> <u>V</u> <u>N</u> <u>Y</u> <u>A</u>
potapyrase	123	<u>E</u> <u>L</u> <u>G</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>M</u> <u>L</u> <u>K</u> <u>G</u> <u>D</u> <u>A</u> <u>A</u> <u>E</u> <u>K</u> <u>I</u> <u>L</u> <u>Q</u> <u>A</u> <u>V</u> <u>R</u> <u>N</u> <u>L</u> <u>V</u> <u>K</u> <u>N</u> <u>Q</u> <u>S</u> <u>T</u> <u>F</u> <u>-</u> <u>H</u> <u>S</u> <u>K</u> <u>D</u> <u>Q</u> <u>W</u> <u>V</u> <u>T</u> <u>I</u> <u>L</u> <u>D</u> <u>G</u> <u>T</u> <u>Q</u> <u>E</u> <u>G</u> <u>S</u> <u>Y</u> <u>M</u> <u>W</u> <u>A</u> <u>A</u> <u>I</u> <u>N</u> <u>Y</u> <u>L</u>
CD39L2	178	<u>V</u> <u>L</u> <u>K</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>P</u> <u>G</u> <u>E</u> <u>K</u> <u>A</u> <u>Q</u> <u>K</u> <u>L</u> <u>L</u> <u>Q</u> <u>K</u> <u>V</u> <u>K</u> <u>E</u> <u>V</u> <u>F</u> <u>K</u> <u>-</u> <u>A</u> <u>S</u> <u>P</u> <u>F</u> <u>-</u> <u>L</u> <u>V</u> <u>G</u> <u>D</u> <u>D</u> <u>C</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>N</u> <u>G</u> <u>T</u> <u>D</u> <u>E</u> <u>G</u> <u>V</u> <u>S</u> <u>A</u> <u>W</u> <u>I</u> <u>T</u> <u>I</u> <u>N</u> <u>F</u> <u>L</u>
CD39L4	126	<u>V</u> <u>L</u> <u>K</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>P</u> <u>E</u> <u>H</u> <u>K</u> <u>A</u> <u>K</u> <u>A</u> <u>L</u> <u>L</u> <u>F</u> <u>E</u> <u>V</u> <u>K</u> <u>E</u> <u>I</u> <u>F</u> <u>R</u> <u>-</u> <u>K</u> <u>S</u> <u>P</u> <u>F</u> <u>-</u> <u>L</u> <u>V</u> <u>P</u> <u>K</u> <u>G</u> <u>S</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>D</u> <u>G</u> <u>S</u> <u>D</u> <u>E</u> <u>G</u> <u>I</u> <u>L</u> <u>A</u> <u>W</u> <u>V</u> <u>T</u> <u>V</u> <u>N</u> <u>F</u> <u>L</u>
dNTPase	156	<u>V</u> <u>L</u> <u>K</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>P</u> <u>A</u> <u>S</u> <u>K</u> <u>A</u> <u>E</u> <u>N</u> <u>I</u> <u>L</u> <u>N</u> <u>A</u> <u>V</u> <u>R</u> <u>D</u> <u>L</u> <u>F</u> <u>A</u> <u>-</u> <u>K</u> <u>S</u> <u>E</u> <u>F</u> <u>-</u> <u>S</u> <u>V</u> <u>D</u> <u>M</u> <u>D</u> <u>A</u> <u>V</u> <u>E</u> <u>I</u> <u>M</u> <u>D</u> <u>G</u> <u>T</u> <u>D</u> <u>E</u> <u>G</u> <u>I</u> <u>F</u> <u>S</u> <u>W</u> <u>F</u> <u>T</u> <u>V</u> <u>N</u> <u>F</u> <u>L</u>
YGDPase	123	<u>A</u> <u>V</u> <u>K</u> <u>A</u> <u>T</u> <u>A</u> <u>G</u> <u>L</u> <u>R</u> <u>L</u> <u>L</u> <u>G</u> <u>D</u> <u>A</u> <u>K</u> <u>S</u> <u>K</u> <u>I</u> <u>L</u> <u>S</u> <u>A</u> <u>V</u> <u>R</u> <u>D</u> <u>H</u> <u>L</u> <u>E</u> <u>K</u> <u>D</u> <u>Y</u> <u>P</u> <u>F</u> <u>P</u> <u>V</u> <u>E</u> <u>G</u> <u>D</u> <u>G</u> <u>V</u> <u>S</u> <u>I</u> <u>M</u> <u>G</u> <u>G</u> <u>D</u> <u>E</u> <u>E</u> <u>G</u> <u>V</u> <u>F</u> <u>A</u> <u>W</u> <u>I</u> <u>T</u> <u>T</u> <u>N</u> <u>Y</u> <u>L</u>

FIG. 9B



ACR IV

180	peaGDP	LGNL	GKKY	TK	- -	TVGV	IDL	GGGS	VQ	MAY	AV	SK	KT	AK	NA	PK	V	AD	GD	DD	PY	I	KK	V	V	L	K	G	I	P	Y	D																			
182	potapyrase	LGNL	GKDY	KS	- -	TTAT	IDL	GGGS	VQ	MAY	AI	SN	EQ	FA	K	AP	Q	NE	DG	-	EP	Y	V	Q	Q	K	H	L	M	S	K	D	Y	N																	
236	CD39L2	TGSL	KTP	GS	- -	SVGM	LDL	GGGS	TQ	IA	FL	PR	VE	G	- - -	-	-	-	TL	QA	SP	PG	YL	T	A	L	R	M	F	N	R	T	Y	K																	
184	CD39L4	TGQL	HGHR	QE	- -	TVGT	LDL	GGAS	TQ	IT	FL	PQ	FE	K	- - -	-	-	-	TL	EQ	TP	RG	YL	T	S	F	E	M	F	N	S	T	Y	K																	
214	dNTPase	LGR	L	SK	T	N	QA	- -	AA	- -	LD	L	GGGS	TQ	VT	FS	P	T	D	P	D	- - -	-	-	-	Q	V	P	V	Y	D	K	-	Y	M	H	E	V	V	T	S	S	K	K	I	N					
183	YGD Pase	LGN	I	G	A	N	G	P	K	L	P	T	A	A	V	F	DL	GGGS	TQ	IV	FE	P	T	F	P	I	N	E	K	M	V	- - -	-	-	-	D	G	E	H	K	F	D	L	K	F	G	D	E	N	Y	T



peaGDP	238	<u>LYVHSY</u> <u>LHFGR</u> <u>EASRAE</u> <u>ILKLT</u> <u>PRSP</u> ----- <u>NPCLLAGFNG</u> ----- <u>IY</u>
potapyrase	239	<u>LYVHSY</u> <u>LYNYGQ</u> <u>LAGRAE</u> <u>IFKARNES</u> ----- <u>NPCALEGCDG</u> ----- <u>YY</u>
CD39L2	289	<u>LYSYSY</u> <u>LYGLGL</u> <u>MSARLA</u> <u>ILGGVEGQ</u> <u>PAKD</u> <u>GKELV</u> ----- <u>SPCLSPSFKG</u> ----- <u>E-W</u>
CD39L4	237	<u>LYTHSY</u> <u>LYGFGL</u> <u>KAAARLA</u> <u>TLGALE</u> <u>TE</u> - <u>GTDGHTFR</u> ----- <u>SACLPRLWA</u> ----- <u>E-W</u>
dNTPase	264	<u>VFTHSY</u> <u>LYGLGL</u> <u>MAARH</u> <u>AVF</u> --- <u>THGYKKED</u> <u>TVLE</u> ----- <u>SVCVNP</u> <u>IIAN</u> ----- <u>RTW</u>
YGD Pase	238	<u>LYQFSH</u> <u>LGYGL</u> <u>KEGRN</u> <u>KVNSV</u> <u>LVENAL</u> <u>KDGKI</u> <u>LKGDNT</u> <u>KTHQL</u> <u>SSPCLP</u> <u>PKVNAT</u> <u>NEKVT</u>

FIG. 9C



peaGDP	276	<u>T</u> <u>Y</u> <u>S</u> <u>G</u> <u>E</u> <u>E</u> <u>F</u> <u>K</u> <u>A</u> <u>T</u> <u>A</u> <u>Y</u> <u>T</u> <u>S</u> <u>G</u> - <u>A</u> <u>N</u> <u>F</u> <u>N</u> <u>K</u> <u>C</u> <u>K</u> <u>N</u> <u>T</u> <u>I</u> <u>R</u> <u>K</u> <u>A</u> <u>L</u> <u>K</u> <u>L</u> <u>N</u> <u>Y</u> <u>P</u> <u>C</u> <u>P</u> <u>Y</u> <u>Q</u> <u>N</u> <u>C</u> <u>T</u> <u>F</u> <u>G</u> <u>G</u> <u>I</u> <u>W</u> <u>N</u> <u>G</u> <u>G</u> - - - <u>G</u> <u>G</u> <u>N</u> <u>G</u> <u>Q</u> <u>K</u> <u>N</u>
potapyrase	277	<u>S</u> <u>Y</u> <u>G</u> <u>G</u> <u>V</u> <u>D</u> <u>Y</u> <u>K</u> <u>V</u> <u>K</u> <u>A</u> <u>P</u> <u>K</u> <u>K</u> <u>G</u> - <u>S</u> <u>S</u> <u>W</u> <u>K</u> <u>R</u> <u>C</u> <u>R</u> <u>R</u> <u>L</u> <u>T</u> <u>R</u> <u>H</u> <u>A</u> <u>L</u> <u>K</u> <u>I</u> <u>N</u> <u>A</u> <u>K</u> <u>C</u> <u>N</u> <u>I</u> <u>E</u> <u>E</u> <u>C</u> <u>T</u> <u>F</u> <u>N</u> <u>G</u> <u>V</u> <u>W</u> <u>N</u> <u>G</u> <u>G</u> - - - <u>G</u> <u>G</u> <u>D</u> <u>G</u> <u>Q</u> <u>K</u> <u>N</u>
CD39L2	335	<u>E</u> <u>H</u> <u>A</u> <u>E</u> <u>V</u> <u>T</u> <u>Y</u> <u>R</u> <u>V</u> <u>S</u> <u>G</u> <u>Q</u> <u>K</u> <u>A</u> <u>A</u> <u>S</u> <u>L</u> <u>H</u> <u>E</u> <u>L</u> <u>C</u> <u>A</u> <u>A</u> <u>R</u> - - - <u>V</u> <u>S</u> <u>E</u> <u>V</u> - - - <u>L</u> <u>Q</u> <u>N</u> <u>R</u> <u>V</u> - - - - <u>H</u> <u>R</u> <u>T</u> - - - - <u>E</u> <u>E</u> <u>V</u> <u>K</u> <u>H</u> <u>V</u> <u>D</u>
CD39L4	282	<u>I</u> <u>F</u> <u>G</u> <u>G</u> <u>V</u> <u>K</u> <u>Y</u> <u>Q</u> <u>Y</u> <u>G</u> <u>G</u> <u>N</u> <u>Q</u> <u>E</u> <u>G</u> <u>E</u> <u>V</u> <u>G</u> <u>F</u> <u>E</u> <u>P</u> <u>C</u> <u>Y</u> <u>A</u> <u>E</u> - - - <u>V</u> <u>L</u> <u>R</u> <u>V</u> - - - - <u>V</u> <u>R</u> <u>G</u> <u>K</u> <u>L</u> - - - - <u>H</u> <u>Q</u> <u>P</u> - - - - <u>E</u> <u>E</u> <u>V</u> <u>Q</u> <u>R</u> <u>G</u> <u>S</u>
dNTPase	308	<u>T</u> <u>Y</u> <u>G</u> <u>N</u> <u>V</u> <u>Q</u> <u>Y</u> <u>K</u> <u>V</u> <u>S</u> <u>G</u> <u>K</u> <u>E</u> <u>N</u> <u>G</u> <u>K</u> <u>S</u> <u>S</u> <u>A</u> <u>E</u> <u>Q</u> <u>P</u> <u>I</u> <u>V</u> <u>D</u> <u>F</u> <u>D</u> <u>A</u> <u>C</u> <u>L</u> <u>E</u> <u>L</u> - - - - <u>V</u> <u>K</u> <u>S</u> <u>K</u> <u>V</u> <u>M</u> <u>P</u> <u>L</u> <u>V</u> <u>K</u> <u>P</u> <u>K</u> <u>P</u> - - - - <u>F</u> <u>T</u> <u>L</u> <u>K</u> <u>Q</u> <u>H</u> <u>A</u>
YGD Pase	298	<u>L</u> <u>E</u> <u>S</u> <u>K</u> <u>E</u> <u>T</u> <u>Y</u> <u>T</u> <u>I</u> <u>D</u> <u>F</u> <u>I</u> <u>G</u> <u>P</u> <u>D</u> <u>E</u> <u>P</u> <u>S</u> <u>G</u> <u>A</u> <u>Q</u> <u>C</u> <u>R</u> <u>F</u> <u>L</u> <u>T</u> <u>D</u> <u>E</u> <u>I</u> <u>L</u> <u>N</u> <u>K</u> <u>D</u> <u>A</u> <u>Q</u> <u>C</u> <u>Q</u> <u>S</u> <u>P</u> <u>P</u> <u>C</u> <u>S</u> <u>F</u> <u>N</u> <u>G</u> <u>V</u> <u>H</u> <u>Q</u> <u>P</u> <u>S</u> <u>L</u> <u>V</u> <u>R</u> <u>T</u> <u>F</u> <u>K</u> <u>E</u> <u>S</u> <u>N</u> <u>D</u>
peaGDP	332	<u>L</u> <u>P</u> <u>A</u> <u>S</u> <u>S</u> <u>F</u> <u>F</u> <u>Y</u> <u>L</u> <u>P</u> <u>E</u> <u>D</u> <u>T</u> <u>G</u> <u>M</u> <u>V</u> <u>D</u> <u>A</u> <u>S</u> <u>T</u> <u>P</u> <u>N</u> <u>F</u> <u>I</u> <u>L</u> <u>R</u> <u>P</u> <u>V</u> <u>D</u> <u>I</u> <u>E</u> <u>T</u> <u>K</u> <u>A</u> <u>K</u> <u>E</u> <u>A</u> <u>C</u> <u>A</u> <u>L</u> <u>N</u> <u>F</u> <u>E</u> <u>D</u> <u>A</u> <u>K</u> <u>S</u> <u>T</u> <u>Y</u> <u>P</u> <u>P</u> <u>F</u> <u>L</u> <u>D</u> <u>K</u> <u>K</u> <u>N</u> <u>V</u> <u>A</u> <u>S</u>
potapyrase	333	<u>I</u> <u>H</u> <u>A</u> <u>S</u> <u>S</u> <u>F</u> <u>F</u> <u>Y</u> <u>D</u> <u>I</u> <u>G</u> <u>A</u> <u>Q</u> <u>V</u> <u>G</u> <u>I</u> <u>V</u> <u>D</u> <u>T</u> <u>K</u> <u>F</u> <u>P</u> <u>S</u> <u>A</u> <u>L</u> <u>A</u> <u>K</u> <u>P</u> <u>I</u> <u>Q</u> <u>Y</u> <u>L</u> <u>N</u> <u>A</u> <u>A</u> <u>K</u> <u>V</u> <u>A</u> <u>C</u> <u>Q</u> <u>T</u> <u>N</u> <u>V</u> <u>A</u> <u>D</u> <u>I</u> <u>K</u> <u>S</u> <u>I</u> <u>F</u> <u>P</u> <u>K</u> <u>T</u> <u>Q</u> <u>D</u> <u>R</u> <u>N</u> <u>I</u> - <u>P</u>
CD39L2	379	<u>F</u> <u>Y</u> <u>A</u> <u>F</u> <u>S</u> <u>Y</u> <u>Y</u> <u>D</u> <u>L</u> <u>A</u> <u>A</u> <u>G</u> <u>V</u> <u>G</u> <u>L</u> <u>I</u> <u>D</u> <u>A</u> <u>E</u> - <u>K</u> <u>G</u> <u>G</u> <u>S</u> <u>L</u> <u>V</u> <u>V</u> <u>G</u> <u>D</u> <u>F</u> <u>E</u> <u>I</u> <u>A</u> <u>A</u> <u>K</u> <u>Y</u> <u>V</u> <u>C</u> <u>R</u> <u>T</u> - - - - - <u>L</u> <u>E</u> <u>T</u> <u>Q</u> <u>P</u> <u>Q</u> <u>S</u> <u>S</u> <u>P</u>
CD39L4	326	<u>F</u> <u>Y</u> <u>A</u> <u>F</u> <u>S</u> <u>Y</u> <u>Y</u> <u>D</u> <u>R</u> <u>A</u> <u>V</u> <u>D</u> <u>T</u> <u>D</u> <u>M</u> <u>I</u> <u>D</u> <u>Y</u> <u>E</u> - <u>K</u> <u>G</u> <u>G</u> <u>I</u> <u>L</u> <u>K</u> <u>V</u> <u>E</u> <u>D</u> <u>F</u> <u>E</u> <u>R</u> <u>K</u> <u>A</u> <u>R</u> <u>E</u> <u>V</u> <u>C</u> <u>D</u> <u>N</u> - - - - - <u>L</u> <u>E</u> <u>N</u> <u>F</u> <u>T</u> <u>S</u> <u>G</u> <u>S</u> <u>P</u>
dNTPase	360	<u>V</u> <u>A</u> <u>A</u> <u>F</u> <u>S</u> <u>Y</u> <u>F</u> <u>F</u> <u>E</u> <u>R</u> <u>A</u> <u>I</u> <u>E</u> <u>S</u> <u>G</u> <u>L</u> <u>V</u> <u>D</u> <u>P</u> <u>L</u> - <u>A</u> <u>G</u> <u>G</u> <u>E</u> <u>T</u> <u>T</u> <u>V</u> <u>E</u> <u>A</u> <u>Y</u> <u>R</u> <u>K</u> <u>K</u> <u>A</u> <u>Q</u> <u>E</u> <u>I</u> <u>C</u> <u>A</u> <u>I</u> - - - - - <u>P</u> <u>N</u> <u>D</u> <u>E</u> - - - - <u>Q</u> <u>P</u>
YGD Pase	358	<u>I</u> <u>Y</u> <u>I</u> <u>F</u> <u>S</u> <u>Y</u> <u>F</u> <u>Y</u> <u>D</u> <u>R</u> <u>T</u> <u>R</u> <u>P</u> <u>L</u> <u>G</u> <u>M</u> <u>P</u> <u>L</u> <u>S</u> <u>F</u> <u>T</u> <u>L</u> <u>N</u> <u>E</u> <u>L</u> <u>N</u> <u>D</u> <u>L</u> <u>A</u> <u>R</u> <u>I</u> <u>V</u> <u>C</u> <u>K</u> <u>G</u> <u>E</u> <u>E</u> <u>T</u> <u>W</u> <u>N</u> <u>S</u> <u>V</u> <u>F</u> <u>S</u> <u>G</u> <u>I</u> <u>A</u> <u>G</u> <u>S</u> <u>L</u> - - - <u>D</u> <u>E</u> <u>L</u> <u>E</u> <u>S</u> <u>D</u> <u>S</u>

FIG. 9D

Title: METHODS AND COMPOSITIONS RELATING TO  
CD39-LIKE POLYPEPTIDES AND NUCELIC ACIDS

Applicants: Brian Paul Chadwick et al.

Docket No.: 28110/36120A

46/46



peaGDP	392	<u>Y</u> <u>V</u> <u>C</u> <u>M</u> <u>D</u> <u>L</u> <u>I</u> <u>Y</u> <u>Q</u> <u>Y</u> <u>V</u> <u>L</u> <u>L</u> <u>V</u> <u>D</u> <u>G</u> <u>F</u> <u>G</u> <u>L</u> <u>D</u> <u>P</u> <u>L</u> <u>Q</u> <u>K</u> <u>I</u> <u>T</u> <u>S</u> <u>G</u> <u>K</u> <u>E</u> <u>I</u> <u>E</u> <u>Y</u> <u>Q</u> <u>D</u> <u>A</u> <u>I</u> <u>V</u> <u>E</u> <u>A</u> <u>A</u> <u>P</u> <u>L</u> <u>G</u> <u>N</u> <u>A</u> <u>V</u> <u>E</u> <u>A</u> <u>I</u> <u>S</u> <u>A</u> <u>L</u> <u>P</u> <u>K</u> <u>F</u> <u>E</u> <u>R</u> <u>L</u>
potapyrase	392	<u>Y</u> <u>L</u> <u>C</u> <u>M</u> <u>D</u> <u>L</u> <u>I</u> <u>Y</u> <u>E</u> <u>Y</u> <u>T</u> <u>L</u> <u>L</u> <u>V</u> <u>D</u> <u>G</u> <u>F</u> <u>G</u> <u>L</u> <u>N</u> <u>P</u> <u>H</u> <u>K</u> <u>E</u> <u>I</u> <u>T</u> <u>V</u> <u>I</u> <u>H</u> <u>D</u> <u>V</u> <u>Q</u> <u>Y</u> <u>K</u> <u>N</u> <u>Y</u> <u>L</u> <u>V</u> <u>G</u> <u>A</u> <u>A</u> <u>P</u> <u>L</u> <u>G</u> <u>C</u> <u>A</u> <u>I</u> <u>D</u> <u>L</u> <u>V</u> <u>S</u> <u>S</u> <u>T</u> <u>T</u> <u>N</u> <u>K</u> <u>I</u> <u>R</u> <u>V</u>
CD39L2	428	<u>F</u> <u>S</u> <u>C</u> <u>M</u> <u>D</u> <u>L</u> <u>T</u> <u>Y</u> <u>V</u> <u>S</u> <u>L</u> <u>L</u> <u>L</u> <u>Q</u> <u>E</u> <u>-</u> <u>F</u> <u>G</u> <u>F</u> <u>P</u> <u>R</u> <u>S</u> <u>K</u> <u>V</u> <u>L</u> <u>K</u> <u>L</u> <u>T</u> <u>R</u> <u>K</u> <u>I</u> <u>D</u> <u>N</u> <u>-</u> <u>-</u> <u>-</u> <u>V</u> <u>E</u> <u>T</u> <u>S</u> <u>W</u> <u>A</u> <u>L</u> <u>G</u> <u>A</u> <u>I</u> <u>F</u> <u>H</u> <u>Y</u> <u>I</u> <u>D</u> <u>S</u> <u>L</u> <u>N</u> <u>R</u> <u>Q</u> <u>K</u> <u>S</u> <u>P</u>
CD39L4	375	<u>F</u> <u>L</u> <u>C</u> <u>M</u> <u>D</u> <u>L</u> <u>S</u> <u>Y</u> <u>I</u> <u>T</u> <u>A</u> <u>L</u> <u>L</u> <u>K</u> <u>D</u> <u>G</u> <u>F</u> <u>G</u> <u>F</u> <u>A</u> <u>D</u> <u>S</u> <u>T</u> <u>V</u> <u>L</u> <u>Q</u> <u>L</u> <u>T</u> <u>K</u> <u>K</u> <u>V</u> <u>N</u> <u>N</u> <u>-</u> <u>-</u> <u>-</u> <u>I</u> <u>E</u> <u>T</u> <u>G</u> <u>W</u> <u>A</u> <u>L</u> <u>G</u> <u>A</u> <u>T</u> <u>F</u> <u>H</u> <u>L</u> <u>L</u> <u>Q</u> <u>S</u> <u>L</u> <u>G</u> <u>I</u> <u>S</u> <u>H</u>
dNTPase	406	<u>F</u> <u>M</u> <u>C</u> <u>F</u> <u>D</u> <u>L</u> <u>T</u> <u>F</u> <u>I</u> <u>S</u> <u>T</u> <u>L</u> <u>L</u> <u>R</u> <u>E</u> <u>G</u> <u>F</u> <u>G</u> <u>L</u> <u>N</u> <u>D</u> <u>G</u> <u>K</u> <u>I</u> <u>K</u> <u>L</u> <u>Y</u> <u>K</u> <u>K</u> <u>I</u> <u>D</u> <u>G</u> <u>-</u> <u>-</u> <u>-</u> <u>H</u> <u>E</u> <u>I</u> <u>S</u> <u>W</u> <u>A</u> <u>L</u> <u>G</u> <u>C</u> <u>A</u> <u>Y</u> <u>N</u> <u>V</u> <u>L</u> <u>T</u> <u>S</u> <u>D</u> <u>E</u> <u>K</u> <u>F</u> <u>S</u> <u>N</u> <u>S</u>
YGD Pase	415	<u>H</u> <u>F</u> <u>C</u> <u>L</u> <u>D</u> <u>L</u> <u>S</u> <u>F</u> <u>Q</u> <u>V</u> <u>S</u> <u>L</u> <u>L</u> <u>H</u> <u>T</u> <u>G</u> <u>Y</u> <u>D</u> <u>I</u> <u>P</u> <u>L</u> <u>Q</u> <u>R</u> <u>E</u> <u>L</u> <u>R</u> <u>T</u> <u>G</u> <u>K</u> <u>K</u> <u>I</u> <u>A</u> <u>N</u> <u>K</u> <u>-</u> <u>-</u> <u>-</u> <u>E</u> <u>I</u> <u>G</u> <u>W</u> <u>C</u> <u>L</u> <u>G</u> <u>A</u> <u>S</u> <u>L</u> <u>P</u> <u>L</u> <u>L</u> <u>K</u> <u>A</u> <u>D</u> <u>N</u> <u>W</u> <u>K</u> <u>C</u> <u>K</u> <u>I</u>

peaGDP	452	<u>M</u> <u>Y</u> <u>F</u> <u>V</u>
potapyrase	452	<u>A</u> <u>S</u> <u>S</u> <u>*</u>
CD39L2	483	<u>A</u> <u>S</u> <u>*</u>
CD39L4	429	
dNTPase	462	
YGD Pase	471	<u>Q</u> <u>S</u> <u>A</u>

FIG. 9E